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Abstract 
 
My research focuses on understanding the substrate specificity of the viral 
homolog of the ovarian tumor domain protease superfamily (vOTU) from nairoviruses, 
and the structural reasons for their specificities. The vOTU from the Crimean-Congo 
Hemorrhagic Fever Virus (CCHFV) has been implicated in the down-regulation of the 
innate immune response through its ability to cleave post-translational modifications via 
Ubiquitin (Ub) as well as the Ub-like interferon-stimulated gene 15 (ISG15). vOTU 
homologs have been found in numerous viruses across several families. Moreover, the 
effects of these viruses range in severity from mild flu-like symptoms to mortality 
depending on the species of the infected host. As such, several nairovirus vOTUs 
including those from the Dugbe Virus (DUGV), Erve Virus (ERVEV), and CCHFV were 
subjected to enzymological studies to gain insight into substrate specificity. These studies 
revealed that even vOTUs from the same viral family have differing specificities for Ub 
and ISG15. Furthermore, these preferences extend to include the different polymeric 
moieties of Ub. In order to gain insight into any structural reasoning for these substrate 
predilections, the X-ray crystal structures of the vOTUs from both CCHFV and DUGV 
were each solved covalently bound with Ub. These structures exposed unique secondary 
structure elements compared to other members of the OTU superfamily that offer 
understanding into why certain vOTUs, such as that from CCHFV, can possess robust 
activity for Ub and ISG15. Likewise, the crystallographic data point to the primary 
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structure of the vOTUs as the main driving force for divergence between nairovirus 
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Chapter One: Introduction 
Deubiquitinating enzymes (DUBs) are responsible for the removal of Ubiquitin 
(Ub), an important post-translational modifying protein, from its substrate. Ub is a small 
protein, 76 residues in length, which acts as a cellular signal through post-translational 
attachment to a target protein, and is responsible for a range of activity from trafficking 
and cell division to upregulation and degradation. DUBs can not only edit and remove Ub 
but also Ub-like molecules; those that assume a similar fold to that of Ub and can also act 
as cellular signals. In this chapter I will give a brief overview of: the known functions of 
Ub and a few Ub-like proteins, the five superfamilies of DUBs and what is known of 
their roles in the Ub cycle, a synopsis of the DUB subclass known as the viral ovarian 
tumor domain proteases (vOTUs), and a brief background of viruses from several 
different families that have been found to possess a vOTU. 
Roles of Ubiquitin.  
Ubiquitin (Ub) is a small, 
highly conserved, 76 amino acid 
protein. Ub is attached as a post-
translational modification through a 
three-step enzymatic process. 
Ubiquitination relies on a cascade of 
enzymes by which Ub is activated (E1), 
Figure 1.1. Ubiquitin Conjugation Cascade. 
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conjugated (E2), and finally ligated (E3) to its intended target (Figure 1.1)(8-10). During 
activation the E1 enzyme utilizes ATP to create a thioester bond between the C-terminus 
of the Ub and a cysteine on the E1. From there the Ub is transferred to the active site 
cysteine of the E2. After that the Ub is attached to the ε-amino group of a lysine residue 
(K) located on the target protein via the E3. In humans there are over 600 E3 enzymes, 38 
E2 enzymes, and 2 E1 enzymes.  
Ubiquitination is further complicated by the fact that Ub itself can be 
ubiquitinated at its N-terminus (linear) or at one of its seven lysines (6, 11, 27, 29, 33, 48, 
or 63). Furthermore, chains consisting of more than one type of linkage (mixed) also exist 
(Figure 1.2). Modification with a single Ub moiety (Mono-Ub; Figure 1.2a) has been 
linked to DNA repair, gene expression, and endocytosis(11-14). Attachment of several 
mono-Ub proteins to the same target is known as multimonomeric Ub (multimono-Ub; 
Figure 1.2b) and has also been implicated in endocytosis(15). In the case of polymeric-Ub 
chains (poly-Ub), the protein’s fate is determined by the type of Ub-linkage present 
(Figure 1.2 c-e). A poly-Ub chain is designated by the lysine residue that is the site of 
attachment for each subsequent Ub 
protein. For example, K63-linked poly-
Ub indicates that each Ub is attached to 
lysine 63 of the Ub molecule before it. 
These chains can be homogenous or 
mixed, containing linkages at several 
different lysine residues. Each unique Figure 1.2. Different conformations of Ub 
modification. 
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linkage type results in its own unique conformation, which in turn exposes different 
residues and areas for proteins such as DUBs to interact(16).  
Noncanonical forms of poly-Ub—linear and K6, -11, -27, -29, and -33—comprise 
over half of all poly-Ub-conjugated yeast proteins and have been implicated in immune 
system regulation and other key cellular functions(17). Specifically, K29-linked poly-Ub is 
known to facilitate trafficking proteins to the lysosome, whereas K11-linked poly-Ub has 
been implicated in regulating cell division(18). Although their functions have been less 
studied, K6, K27, and K33 appear to possibly act as modulators of immunologically 
relevant signaling pathways(19-21). Unlike the noncanonical linked poly-Ub, the effects of 
K48-linked and K63-linked poly-Ub modifications are better studied. Modification of 
host proteins by K48-linked poly-Ub typically leads to proteasomal degradation, whereas 
K63-linked poly-Ub modifications are implicated in the induction of the type I interferon 
(IFN) response involved in the innate immune response(22, 23). Upon entry into host cells, 
viruses need to outpace innate immunity before the adaptive immune system clears them 
from the organism. The type I IFN-α/β are critical orchestrators of innate immunity(24). 
Previously, a phosphorylation cascade was proposed to singularly instigate the 
production of type I IFNs and proinflammatory cytokines (NF-κB) and the type I IFN 
upregulation of several IFN-stimulated gene with antipathogenic properties through 
JAK1-STAT1/2 signaling (Janus-activated kinase 1–signal transducer and activator of 
transcription 1/2)(25). However, regulation of the IFNI response and activation of NF-κB 
has been shown to go beyond phosphorylation events and also relies on post-translational 
modification by Ub and Ub-like IFN-stimulated gene product 15 (ISG15)(26). In 
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particular, JAK1, STAT1/2, TRAF (Tumor necrosis factor Receptor-Associated Factor), 
and RIG-I (retinoic acid-inducible gene 1), among other IFNI signaling and effector 
proteins, have been observed to undergo ubiquitination or ISGylation(27). 
Ub-Like Proteins 
Ub-like (UBL) proteins are proteins that have a similar fold to that of Ub and also 
act as post-translational modifiers typically through attachment via lysines. Two 
examples of UBL proteins are ISG15 and neural precursor cell expressed, 
developmentally downregulated 8 (NEDD8).  ISG15 is a UBL protein almost twice as 
large as Ub and as such adopts a secondary structure comprised of two domains that each 
shares roughly 30% structural homology to that of Ub. Unlike Ub, ISG15 is not as well 
conserved throughout eukaryotes(28). Beyond the previously mentioned role of ISG15 in 
the IFNI response, ISG15 has been shown to be critical for antiviral activity through 
several means including acting as a Ub antagonist in HIV-1 and Ebola to prevent 
budding, and disruption of the endosomal sorting complexes required for transport 
(ESCRT) pathway in the Avian sarcoma leucosis virus (ASLV)(28). Similarly, NEDD8 is 
a UBL protein involved in the activity of the cullin-RING ligase family of E3 ligases, 
impairment of which has been tied to cancer(29). NEDD 8 is more similar to Ub than 
ISG15 being 81 amino acids in length in its proform and sharing ~80% sequence 
homology(30). Just as Ub conjugation involves a cascade of E1-E2-E3 enzymes, so too 
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DUB Superfamilies.  
DUBs can be classified into five families: Ubiquitin-specific proteases (USPs), 
Josephins, JAB1/MPN/MOV34 metalloenzymes (JAMMs), C-terminal hydrolases 
(UCHs), and ovarian tumor proteases (OTUs). Each DUB has their own substrate 
preference and their role can be separated into three major categories: 1.) Generation of 
free Ub from a transcribed linear fusion of multiple Ub molecules, 2.) Removal of Ub 
from post-translationally modified proteins, or 3.) Editing the length of poly-Ub chains 
(Figure 1.3)(16). 
Members of the UCH superfamily, such as UCH-L1 and L3, have shown the 
ability to only cleave mono-Ub, however, other members such as UCH37 can also cleave 
Figure 1.3. Functions of DUBs 
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poly-Ub(31). USPs make up the largest family of DUBs with over 50 found in humans and 
have previously been shown to preferentially cleave Ub-modified substrates, with each 
member having their own linkage preferences. However, recently USP18 has shown to 
preferentially cleave ISG15-conjugated substrates over Ub(32-34). ATAXIN-3, a Josephin 
DUB, has been shown to effectively trim Ub from K63-linked poly-Ub when the chain 
length was greater than five Ub molecules suggesting a dependence on length, and 
demonstrates increased cleavge of shorter, mixed chains for K63 linkages in both 
homogenous and mixed chains(35). Most JAMM domain DUBs are specific for K63-
linked poly-Ub and can cleave complete poly-Ub chains from their substrate(36). The 
OTU superfamily members can be divided into three subclasses according to their 
sequence homology, otubains, A20-like OTUs, and ubiquitin thioesterase ZRANB1(16). 
Otubain1/2 (OTUB1/2) plays a key role in T cell response and prefers K48-linked poly-
Ub or NEDD8 as a substrate(37). A20 and A20-like Cezanne OTU proteases are negative 
regulators of the NF-κB-mediated inflammation response, selectively cleaving K63-
linked poly-Ub targets. DUBA also shows preference for K63-linked poly-Ub(38). 
Predominantly, OTU proteases have been linked to Ub removal and/or remodeling of Ub-
conjugated proteins, placing them among five protease superfamilies that facilitate signal 
transduction cascades and play key roles in protein stability(16). 
Viral Ovarian Tumor Domain (vOTU) Proteases.  
The most recent protease to be identified as an OTU was the viral ovarian tumor 
domain (vOTU) protease, co-located with the RNA-dependent RNA polymerase (RdRp) 
in the large (L) protein of the Crimean-Congo Hemorrhagic Fever (CCHF) virus(39). 
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Interestingly, as CCHF is a negative-sense, single-stranded RNA virus [ssRNA (-)], no 
protease is required to cleave a viral polypeptide to facilitate viral replication, as is the 
case in positive-sense ssRNA [ssRNA (+)] viruses. Furthermore, recent reports have 
observed that vOTU is not required for RdRp activity and that vOTU protease activity 
has been linked to impairment of the type I IFN response through its deubiquitinating and 
deISGylating activity(39, 40). Additional studies have also tentatively identified the 
presence of vOTU homologs in ssRNA (+) viruses such as the Arterivirus genus of the 
Arteriviridae family, suggesting that they too may facilitate impairment of the type I IFN 
response. vOTUs are unique in that they are the only OTU to have shown both 
deubiquitinating and deISGylating activity(39). In attempts to better understand the OTU 
superfamily, structures of OTUB and A20-like OTU domains have been elucidated(37, 41, 
42). An X-ray structure of the yeast ovarian tumor 1 (yOTU1) domain, which interacts 
with Cdc48 and has a preference for K48-linked poly-Ub, was achieved in complex with 
mono-Ub(43). However, since yOTU1 has a preference for K48-linked Ub and possesses 
low sequence identity to vOTU and other OTU domain proteases, only limited 
information on vOTU could be inferred from the yOTU1 structure. In addition to vOTU, 
several other viral proteases, such as papain-like protease (PLpro) from the severe acute 
respiratory syndrome (SARS) coronavirus, have also shown deubiquitinating and 
deISGylating activity to evade the innate immune system(25, 40, 44, 45). 
Overview of the Coming Chapters.  
Prior to this work, no vOTUs that are known to possess deISGylating activity 
have been structurally solved bound to Ub or UBL substrates. To address this issue and 
 
  9 
elucidate the atomic-level structure of a member from the vOTU superfamily subclass, 
we have obtained the X-ray crystal structure of CCHF vOTU bound with Ub (CCHF 
vOTU-Ub). We also have characterized the CCHF vOTU substrate specificity for mono-
Ub, ISG15, and NEDD8 and compared the results with those from human OTUB2 
(hOTUB2). Additionally, we assessed CCHF vOTU’s deubiquitinating activity toward 
K48- and K63-linked poly-Ub. Furthermore, the increasing number of vOTUs being 
identified in ssRNA (-) and ssRNA (+) viral genomes has spurred speculation of whether 
their vOTUs’ specificity and subsequent role is conserved(39, 46, 47). To gain insight into 
the variability of deubiquitinating and deISGylating activity, the specificity among 
vOTUs from nairoviruses, and how they may compare to non-nairovirus vOTUs, the 
enzymatic parameters and specificity of vOTUs from the CCHF, Dugbe (DUG), and Erve 
nairoviruses, as well as the tenuivirus Turnip Yellow Mosaic Virus in regard to Ub, poly-
Ub, and ISG15 moieties were determined. Furthermore, the X-ray crystal structure of the 
vOTU from DUGV bound with Ub was obtained and compared to that of CCHF vOTU-
Ub to assess the potential origins of any detected variability among nairovirus vOTUs. 
The results of the structural analysis implicated the primary structure as the main source 
of substrate specificity fluctuations. By comparing the structure of vOTUs from DUGV 
and CCHFV bound to Ub, key amino acid positions within nairovirus vOTUs that 
influence activity were identified. 
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Chapter Two: Analysis of a vOTU from the CCHF Virus in Complex with 
Covalently Bonded Ub  
Abstract 
Crimean-Congo hemorrhagic fever (CCHF) virus is a tick-borne, negative-sense, 
single-stranded RNA [ssRNA (-)] nairovirus that produces fever, prostration, and severe 
hemorrhages in humans. With fatality rates for CCHF ranging up to 70% based on 
several factors, CCHF is considered a dangerous emerging disease. Originally identified 
in the former Soviet Union and the Congo, CCHF has rapidly spread across large sections 
of Europe, Asia, and Africa. Recent reports have identified a viral homolog of the ovarian 
tumor protease superfamily (vOTU) within its large (L) protein. This protease has 
subsequently been implicated in downregulation of the type I interferon (IFN) immune 
response through cleavage of post-translational modifying proteins ubiquitin (Ub) and the 
Ub-like interferon-simulated gene 15 (ISG15). Additionally, homologs of CCHF vOTU 
have been suggested to perform similar roles in the positive-sense, single-stranded RNA 
[ssRNA (+)] arteriviruses. By utilizing X-ray crystallographic techniques, the structure of 
CCHF vOTU covalently bound to ubiquitin propylamine, a suicide substrate of the 
enzyme, was elucidated to 1.7 Å, revealing unique structural elements that define this 
new subclass of the OTU superfamily. In addition, kinetic studies were carried out with 
aminomethylcoumarin (AMC) conjugates of monomeric Ub, ISG15, and NEDD8 (neural 
precursor cell expressed, developmentally downregulated 8) substrates in order to 
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provide quantitative insights into CCHF vOTU’s preference for Ub and Ub-like 
substrates. 
Introduction 
Crimean-Congo hemorrhagic fever (CCHF) is characterized in humans by the 
sudden onset of fever, myalgia, headache, dizziness, sore eyes, photophobia, and 
hyperanemia as well as severe hemorrhages(25, 48, 49). The causative agent of CCHF is the 
CCHF virus, which is a tick-borne, negative-sense, single-stranded RNA [ssRNA (-)] 
virus of the genus Nairovirus, belonging to the viral family Bunyaviridae. Originally 
named after outbreaks in the former Soviet Union and in the Congo during the mid-20th 
century, the affected area of this disease has rapidly spread to large areas of sub-Saharan 
Africa, the Balkans, Northern Greece, European Russia, Pakistan, the Arabian Peninsula, 
Iran, Afghanistan, Iraq, Turkey, and recently, the Xinjiang province of China(25, 49). The 
CCHF viral genome, as well as those of the closely related Dugbe and Nairobi Sheep 
Disease viruses, consists of three negative-sense RNA segments: small (S), medium (M), 
and large (L). Incubation of CCHF is 5 to 6 days, with fatalities occurring less than 7 
days after signs of infection. Fatality rates for patients infected with the CCHF virus 
ranged from 5% to 70%, depending on phylogenetic variation of the virus, transmission 
route, treatment facility, and the reporting and confirmation of the case statistics(25, 50-52).  
The innate immune system serves as the human’s first line of defense from 
invading pathogens, including the CCHF virus. The type I interferon (IFN) response 
comprises a key component of this system by upregulating more than 300 IFN-stimulated 
genes (ISGs) whose products detect viral molecules, promote amplification of the type I 
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IFN response, modulate other signaling pathways, and directly provide antiviral 
activity(53). Regulation of the type I IFN response has been shown to rely on post-
translational modification by ubiquitin (Ub) and the Ub-like interferon-simulated gene 15 
(ISG15)(39, 54). Both Ub and ISG15 are expressed in a proform and cleaved to leave a 
double-glycine C terminus that forms an isopeptide bond with predominantly the ε-NH2 
of lysine (K) residues of a target protein through a three step enzymatic process. In 
addition to forming isopeptide bonds with target proteins, Ub, which contains seven 
lysine residues, has been observed to form polymeric ubiquitin (poly-Ub) chains. The 
most studied of these moieties are K29-linked, K48-linked, and K63-linked poly-Ub. 
While K29-linked and K48-linked polyubiquitination of proteins leads to their 
degradation in the lysosome and proteasome, respectively, conjugation of K63-linked 
poly-Ub to proteins has an activating effect, resulting in an enhanced type I IFN 
response(22, 23, 55-57). Currently, more than 150 proteins have been identified as forming 
conjugates with ISG15, with the number of proteins forming Ub conjugates far exceeding 
that(37, 45). A subset of type I IFN signaling and effector proteins that Ub and ISG15 have 
been shown to stabilize includes JAK1, STAT1/2, double-stranded RNA-dependent 
protein kinase (PKR), myxovirus-resistant protein A (MxA), and retinoic acid-inducible 
gene 1 (RIG-I)(27). MxA has particularly shown to be important in type I IFN response to 
CCHF infection. RIG-I and several other proteins have also been shown to be targets for 
K63-linked poly-Ub(58). 
Recently, investigators have identified a cysteine viral ovarian tumor domain 
(vOTU) protease colocated with the RNA-dependent RNA polymerase (RdRp) in the L 
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protein of the CCHF virus(39). Interestingly, as CCHF is an ssRNA (-) virus, no protease 
is required to cleave a viral polypeptide to facilitate viral replication as in positive-sense 
ssRNA [ssRNA (+)] viruses. Furthermore, recent reports have observed that vOTU is not 
required for RdRp activity and for vOTU protease activity linked to impairment of the 
type I IFN response through its deubiquitinating and deISGylating activity(39, 40). Since 
the discovery of the first ovarian tumor domain (OTU) protease in Drosophila oogenesis 
and prior to the identification of vOTU, OTU superfamily members could be divided into 
three subclasses according to their sequence homology, otubains, A20-like OTUs, and 
ubiquitin thioesterase ZRANB1(16). With the addition of the viral OTU subclass, OTU 
superfamily members in more than 100 eukaryotic, bacterial, and viral proteins have now 
been identified(40, 43). However, CCHF vOTU is unique in that it is the only OTU to have 
shown both deubiquitinating and deISGylating activity(39). Although an X-ray structure of 
the yeast ovarian tumor 1 (yOTU1) domain was achieved in complex with mono-Ub, 
only limited information on vOTUs could be obtained by comparison since yOTU1 
possesses low sequence identity to CCHF vOTU and other OTU domain proteases (43). 
Still, no viral proteases that are known to possess deISGylating activity have been 
visualized as being bound to Ub or Ub-like substrates. To address this issue and elucidate 
the atomic-level structure of a member from the viral OTU superfamily subclass, we have 
obtained the X-ray crystal structure of CCHF vOTU bound with Ub (CCHF vOTU-Ub). 
We also have characterized the CCHF vOTU substrate specificity for mono-Ub, ISG15, 
and NEDD8 and compared the results with those from human OTUB2 (hOTUB2). 
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Additionally, we assessed vOTU’s deubiquitinating activity toward K48- and K63-linked 
poly-Ub.  
Methods 
This research was supported in part by grants from the Partners in Scholarship of 
the University of Denver. Data sets were collected at the Life Sciences Collaborative 
Access Team (LS-CAT) 21-ID-D and 21-ID-F beamlines at the Advanced Photon 
Source, Argonne National Laboratory. Use of the Advanced Photon Source was 
supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy 
Sciences, under contract DE-AC02-06CH11357. Use of the LS-CAT Sector 21 was 
supported by the Michigan Economic Development Corporation and the Michigan 
Technology Tri-Corridor for the support of this research program (grant 085P1000817). 
Furthermore, I thank Keith Wilkinson and Maxim Balakirev for their gifts of Ub 
and hOTUB2 expression plasmids, respectively, as well as Stephan Ray for assistance in 
performing static light scattering. 
Structural and sequence alignment. 
The alignment of OTUs in Figure 2.1a was generated using two Protein3Dfit 
alignments, vOTU (3PRP) to yOTU1 (3BY4) and vOTU (3PRP) to OTUB2 (1TFF)(59). 
These structural alignments and the amino acid sequence of the NSP2 from porcine 
reproductive and respiratory syndrome virus (PRRSV) were assembled using 
CLUSTALWPROF and TEXSHADE (http://workbench.sdsc.edu/) with the following 
settings: matrix, gonnet; gap-opening penalty, 11; gap extension penalty, 1; and lambda 
ratio, 0.85. Amino acids are color coded according to their being nonconserved (white 
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background), similar (lime green background), conserved (green background), or 
completely conserved (dark-green background, orange lettering) across the four 
sequences. The Ub and Ub-like alignment in Figure 2.1b was generated using 
CLUSTALW and TEXSHADE with the same settings used for alignment of the OTUs. 
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Figure 2.1.  Sequence alignments of various OTU proteases and of Ub and Ub-like proteins. (a) OTUs 
are from CCHF virus (vOTU; GenBank accession no. AAQ98866.2), Saccharomyces cerevisiae (yOTU1; 
PDB accession no. 3BY4_A), PRRSV (NSP2PC; GenBank accession no. ACO06904.1), and Homo 
sapiens Otubain2 (PDB accession no. 1TFF_A). Secondary structure of vOTU according to the defined 
secondary structure of proteins (DSSP) algorithm is represented by blue cylinders (helical regions), brown 
arrows (β-sheet regions), and blue lines (loops). Breaks denote regions where vOTU does not have 
residues. Residues involved in vOTU’s catalytic triad are outlined in black boxes. Residues outlined in 
orange boxes represent those involved in oxyanion hole formation. Colored bars below the sequence 
alignment indicate vOTU and yOTU1 positions within 4 Å of Ub as determined by the Contact program of 
the CCP4 suite(5). Bars under vOTU unique positions are colored light blue with bars under unique yOTU1 
positions in red. Equivalent positions in both vOTU and yOTU1 are shown in purple. Positions that form 
significant salt bridge and H-bond interactions are highlighted by an asterisk. (b) Ub and Ub-like proteins 
from H. sapiens (PDB accession no. 1UBQ_A), NEDD8 (GenBank accession no. CAG28590), and ISG15 
(PDB accession no. 1Z2M_A). Colored bars below the sequence alignment indicate Ub positions within 4 
Å of either vOTU and yOTU1 as determined by the Contact program of the CCP4 suite(5). Bars colored 
light blue and red indicate Ub positions that interact solely with vOTU and yOTU1, respectively. Purple 
bars indicate Ub residues within 4 Å of both vOTU and yOTU1. Amino acids are color coded according to 
their being nonconserved (white background), similar (lime green background), conserved (green 
background), or completely conserved (dark-green background, orange lettering) across the four sequences. 
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Construction of CCHF vOTU and substrate proteins. 
A CCHF vOTU expression construct was obtained by use of an Escherichia coli 
(E. coli) BL21 codon-optimized synthesis of the first 169 amino acids from the L protein 
in CCHFV (GenBank accession no. AAQ98866.2) by Biobasic, Inc. Along with the 
vOTU portion of the L protein, six histidine codons and a stop codon were added to the 
genes in order to provide for a C terminus histidine tag. The resulting gene was 
incorporated into a pET11a plasmid using NdeI and BamHI restriction sites. The 
construct was introduced into E. coli BL21 (DE3) competent cells optimized for 
expression by heat shock transformation. The resulting plasmid was then purified, 
restriction analyzed, and sequenced to verify the construct. Constructs of expression 
plasmids for OTUB2 as well as truncated Ub to be C-terminally modified with 3-
bromopropylamine were designed according to previously established studies(42, 43, 60). 
Expression and production of CCHF vOTU and Ub-Br3. 
For vOTU enzymatic studies, E. coli harboring CCHFV vOTU was grown at 
37°C in 6 liters of Luria-Bertani (LB) broth containing 100 µg of ampicillin/mL until the 
optical density at 600 nm reached 0.6. Expression of the vOTU gene was induced by the 
addition of IPTG (isopropyl-β-D-thiogalactopyranoside) to a final concentration of 0.8 
mM. The culture was further grown for 4 h at 37°C and then centrifuged at 6,000g for 10 
min. For incorporation of selenomethionyl (Se-Met) into CCHF vOTU for crystal 
growth, the BL21 (DE3) E. coli harboring vOTU was grown in minimal medium 
supplemented with 19 amino acids (all except methionine). L-Selenomethionine (100 mg 
per liter; EMD Chemicals) was added immediately before overnight induction at 25°C. 
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OTUB2 was expressed using previously established protocols(42). Cells were collected 
and stored at -80°C until use. CCHF vOTU- and OTUB2-containing cell pellets were 
lysed by the addition of buffer A (500 mM NaCl, 50 mM Tris-HCl [pH 8.0]) containing 5 
mg of lysozyme. The solutions were then sonicated using a Fisher Scientific series 150 
sonicator on ice at 30% power with 5-s pulses for 5 min. Insoluble debris was removed 
by centrifugation at 26,000g for 45 min. The clarified extracts were filtered with a 45-µm 
filter and loaded directly onto Ni-nitrilotriacetic acid (NTA) agarose resin (Qiagen) pre-
equilibrated in buffer A. The column was then washed with two column volumes of 
buffer A followed by five column volumes of a buffer A supplemented with 10 mM 
imidazole solution. The protein was eluted using five column volumes of a buffer A 
supplemented with 250 mM imidazole solution. The elution was applied to a Superdex-
200 Hiload 26/60 FPLC column pre-equilibrated with buffer B (100mM NaCl, 5 mM 
HEPES [pH 7.4], 2 mM dithiothreitol [DTT]) and eluted at a flow rate of 1.5 mL/min. 
Fractions were pooled according to the chromatogram, concentrated to 10 mg/mL in a 
GE Vivaspin centrifuge concentrator with a 10-kDa molecular mass cutoff and filtered 
through a 0.65-µm Amicon spin filter. Purity of OTUB2 and CCHF vOTU was assessed 
by use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).  
Truncated Ub (residues 1 to 75) was expressed according to previously 
established protocols with the exception that after the IPTG induction, the culture was 
grown overnight at 25°C(43, 60). E. coli BL21-CodonPlus pellets containing Ub (1 to 75) 
were lysed with buffer C (25 mM HEPES [pH 6.8], 50 mM sodium acetate, and 75 mM 
NaCl), which was augmented with 0.16% Triton X-100. As with the CCHF vOTU and 
 
  19 
OTUB2 preparations, the solution was then sonicated on ice at 30% power with 5-s 
pulses for 5 min. Insoluble debris was removed by centrifugation at 30,000g for 45 min. 
The clarified extract was filtered with a 45-µm filter and then poured over a chitin 
column pre-equilibrated with buffer C. The column was washed with three column 
volumes of buffer C, followed by resuspension in two column volumes of a solution of 
buffer C supplemented with 100 mM sodium 2-mercaptoethanesulfonate (MESNA). The 
resuspension was rocked gently overnight at 4°C and eluted by filtering through a XK 
26/40 GE column. The resulting Ub thioester was then derivatized with 3-
bromopropylamine (Ub-Br3) according to previously described methods(43, 60). Purity of 
Ub-Br3 was assessed by use of 10 to 20% Ready Gel Tris-Tricine gels (Bio-Rad, CA). 
All final protein concentrations were determined by absorbance at 280 nm using an 
experimentally determined extinction coefficient(61).  
Site-directed mutagenesis of the CCHF vOTU gene. 
CCHF vOTU C40A, W99A, H151A, and D153A were created by using 
QuikChange site-directed mutagenesis according to the manufacturer’s protocol (Agilent 
Technologies, Inc.). The resulting mutant plasmids were introduced into E. coli XL1-
Blue Supercompetent cells by heat shock transformation and were then propagated, 
purified for sequence verification, and transformed into E. coli BL21 (DE3) cells for 
enzyme expression. The complete coding regions for all mutant enzymes were sequenced 
by GenScript, Inc. 
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Fluorescent deubiquitination and deISGylation assay. 
All assays were performed with 100 mM NaCl, 50 mM HEPES [pH 7.5], 0.01 
mg/mL bovine serum albumin (BSA), and 5 mM DTT, by using a Corning Costar half-
volume 96-well plate with a final volume of 50 µL in duplicate. The rates of the reactions 
for comparison of CCHF vOTU and OTUB2 were observed using a Synergy HTTR 
multimode plate reader (Bio-Tek) thermostated at 23°C. Specifically, the increase in 
fluorescence (excitation λ, 360 nm; emission, 460 nm) of 7-amino-4-methylcourmarin 
(AMC) upon cleavage from human Ub-AMC, ISG15-AMC, and NEDD8-AMC 
substrates obtained from Boston Biochem, MA, was monitored. The extinction 
coefficients for all three substrates were determined by adding excess CCHF vOTU to 
various concentrations of each substrate and allowing the reaction to run until 
completion. The resulting maximum fluorescence values were plotted to determine the 
slope and subsequently the extinction coefficients.  
To determine vOTU’s KM values for Ub-AMC, ISG15-AMC, and NEDD8-AMC, 
the substrate concentration was varied from 0 to 50 µM. The initial rates were fitted to the 
Michaelis-Menten equation, ν = Vmax  / (1 / (KM / [S])), using the enzyme kinetics (v. 1.3) 
module of SigmaPlot (v. 10.0; SPSS, Inc.) in order to calculate KM and Vmax. OTUB2 
was only assessed using a substrate concentration of 2 µM for each of the three 
substrates. 
Deubiquitinating gel shift assay. 
For K63-linked and K48-linked poly-Ub deubiquitinating assays, tetra- and di-Ub 
linked by either K48 or K63 isopeptide bonds were purchased from Boston Biochem and 
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Enzo Life Sciences. These poly-Ub substrates (10 µM) were incubated with CCHF 
vOTU (10 nM) in a reaction buffer (100 mM NaCl, 50 mM HEPES [pH 7.5], and 2 mM 
DTT) at 37°C. Reactions were stopped at various times over 1 h by mixing 9 µL of each 
reaction with 2✕ SDS-Tricine sample buffer and boiling for 2 min. 
CCHF vOTU and CCHF vOTU-Ub static light scattering. 
CCHF vOTU and CCHF vOTU-Ub were loaded onto a Wyatt Technology Corp. 
size exclusion column with a pore size of 300 Å pre-equilibrated in buffer D (100 mM 
NaCl, 5 mM HEPES (pH 7.4), 1 mM TCEP-HCl) and attached to a mini Dawn Treos 
(Wyatt, CA). Molecular weights (MW) were calculated using ASTRA (v. 5.3.4.16) 
software and the experimentally determined extinction coefficients for CCHF vOTU and 
CCHF vOTU-Ub(61). 
CCHF vOTU-Ub complex formation and crystallization. 
CCHF vOTU was combined with Ub-Br3 in equal molar ratios, incubated at 37°C 
for 2 h and left overnight at 4°C. Complex formation was monitored using 10 to 20% 
Ready Gel Tris-Tricine gels (Bio-Rad). The CCHF vOTU-Ub complex was purified 
using a GE mono-Q column with buffer E (50 mM Tris-HCl, pH 8.0) and buffer F (50 
mM Tris-HCl [pH 8.0], 1 M NaCl). Fractions were pooled according to the 
chromatogram and loaded onto an AP-1 (Waters) column packed with Superdex-75 pre-
equilibrated with buffer D and eluted at a flow rate of 1.0 mL/min. The resulting CCHF 
vOTU-Ub complex was concentrated in a GE Vivaspin 6 concentrator with a 10-kDa 
molecular mass cutoff and filtered in a 0.65-µm Amicon spin filter. Initial crystal 
conditions for CCHF vOTU-Ub were determined from high-throughput screening of 
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Qiagen Classics and polyethylene glycol I (PEG I) screens in a 96-well sitting drop 
format using an Art Robbins Phoenix robot. Drops contained 0.4 µL of protein solution 
and 0.4 µL of precipitate with a 100 µL reservoir volume. Initial screening resulted in 
several hits; however, a solution containing 100 mM Sodium cacodylate (pH 6.5), 200 
mM magnesium acetate, and 24% PEG 8000 produced the most viable crystals. These 
crystals were optimized using Additive HT Screen from Hampton Research. Final native 
and Se-Met CCHF vOTU-Ub crystals were obtained through vapor diffusion using a 500 
µL reservoir with 4 µL hanging drops mixed 1:1 with protein solution and using a 
precipitant gradient of 22 to 28% PEG 8000, 100 mM Sodium cacodylate (pH 6.5), 100 
to 250 mM magnesium acetate, and 2% n-octyl-β-D-glucoside.  
Data collection and X-ray structural determination of CCHF vOTU-Ub 
complexes. 
All X-ray data sets were collected using crystals mounted on nylon loops and 
flash frozen in liquid nitrogen. For CCHF vOTU-Ub, crystals were submerged in a 5 µL 
cryosolution of 28% PEG 8000, 100 mM Sodium cacodylate (pH 6.5), and 200 mM 
magnesium acetate. Frozen crystals were mounted under a stream of dry N2 at 100 K. A 
single-wavelength anomalous dispersion (SAD) data set with a resolution to 2.3 Å and a 
native data set with a resolution to 1.7 Å were collected at the 21-ID-D and 21-ID-F Life 
Science-Collaborative Access Team beamlines, respectively, at the Advanced Photon 
Source Synchrotron, Argonne National Laboratory. For the SAD data collected, a single 
crystal of the Se-MET containing CCHF vOTU-Ub protein was collected at 0.9789 Å 
with a MarMosaic300 charge-coupled-device (CCD) detector (Rayonix) with the native 
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data collected at 0.97872 Å with a MarMosaic225 CCD detector (Rayonix). All data 
were subsequently processed and scaled using Denzo and Scalepack(62). The heavy atom 
sites from the SAD data were determined using the program HySS from Phenix, 
subsequent phases were determined and refined with Phaser, Resolve was used for 
density modification, and an initial model was autobuilt with Resolve(63-65). The entire 
path was administered via the AutoSol procedure within Phenix(66). Once an initial model 
was constructed utilizing winCoot with the initial phases, the CCHF vOTU-Ub model 
was used to create a molecular replacement solution for the native data using Phaser and 
further refined using iterative cycles of model building and structure refinement using 
Coot and REFMAC, respectively(64, 67, 68). Water molecules were added to 2Fo-Fc density 
peaks that were >1σ using the “Find Water” winCoot program function. The final model 
was checked for structural quality utilizing the CCP4 suite programs Procheck and 
Sfcheck. Structure factors and coordinates have been deposited in the Protein Data Bank 
(PDB), and data processing and refinement statistics are shown in Table 2.1. 
Protein structure accession numbers. Structure factors and coordinates have 
been assigned PDB codes 3PRM (Se-Met) and 3PRP (native). 
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Table 2.1. Data collection and refinement statistics for CCHF vOTU-Ub 
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Results 
Kinetic characterization of CCHF vOTU using Ub-AMC and Ub-like-AMC 
substrates 
Initial reports outlining the domain boundaries of vOTU to the first 169 residues 
of the CCHF viral L protein qualitatively illustrated its ability to cleave both Ub and 
ISG15 conjugates(39). To gain a quantitative understanding of CCHF vOTU’s order of 
preference for Ub and some Ub-like substrates, the cleavage of C-terminally linked 7-
amino-4-methylcourmarin (AMC) conjugates of Ub, ISG15, and NEDD8 by CCHF 
vOTU was monitored. Using initial velocities, the KM and Vmax were determined for each 
substrate (Figure 2.2 a and c). Interestingly, CCHF vOTU possesses 6-fold higher activity 
for Ub than for ISG15. Furthermore, its affinities for NEDD8 are 200-fold and 30-fold 
less than those for Ub and ISG15, respectively. To gain a snapshot of how CCHF vOTU 
compares to other known OTU family members, human OTUB2 (hOTUB2) was also 
assessed using Ub-AMC, ISG15-AMC, and NEDD8-AMC at a fixed substrate 
concentration of 2 µM. Beyond the overall higher deubiquitinating/deISGylating activity 
of CCHF vOTU over hOTUB2 at this concentration and the mutual preference of the 
proteases for Ub-AMC, the proteases differ in their activity toward ISG15-AMC and 
NEDD8-AMC. Similar to results of previous qualitative studies utilizing band shifts by 
SDS-PAGE, hOTUB2 shows minimal deISGylating activity(39) (Figure 2.2b). However, 
it does possess the ability to cleave NEDD8-AMC, reversing the order of CCHF vOTU’s 
preference for ISG15-AMC and NEDD8-AMC. 
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 X-ray structure elucidation of CCHF vOTU-Ub 
To gain a more complete understanding of CCHF vOTU’s mechanism for 
specificity of Ub and Ub-like substrates, Ub with its 76th residue replaced by 
bromopropylamine was used as a CCHF vOTU substrate in order to form the covalent 
complex CCHF vOTU-Ub. Screening CCHF vOTU-Ub against commercial crystal 
precipitant screens, and using an additive screen for optimization, yielded single 
diffracting crystals obtained in a mixture of PEG 8000, sodium cacodylate (pH 6.5), 
magnesium acetate, and n-octyl-β-D-glucoside. A native data set was subsequently 
obtained to 1.7 Å in an I222 space group, but molecular replacement employing 
composite models generated from yOTU1-Ub, OTUB1, and OTUB2 failed to elucidate a 
solution(37, 42, 43). However, using selenomethionyl (Se-Met)-substituted CCHF vOTU-
Ub, phases were obtained using SAD to 2.3 Å in the space group of P212121 (Table 2.1). 
Figure 2.2. CCHF vOTU Ub and Ub-like cleavage activity. (a) 4 nM CCHF vOTU cleavage activity for 
Ub-AMC (Δ), ISG15-AMC (•), and NEDD8-AMC (ο). The initial substrate concentration was 2 µM. Error 
bars represent the average errors. (b) 4 nM hOTUB2 cleavage activity for Ub-AMC (Δ), ISG15-AMC (•), 
and NEDD8-AMC (ο). Error bars represent the average errors. (c) CCHF vOTU KM and Vmax constants for 
substrates in panel a. 
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The resulting solution was two CCHF vOTU-Ub molecules in the asymmetric unit. Once 
an initial model was constructed, a molecular replacement solution also containing two 
CCHF vOTU-Ub molecules in the asymmetric unit was readily obtained from the native 
data set (Figure 2.3a; Table 2.1). In the final model, all of the Ub residues and CCHF 
vOTU residues 1 to 165 per CCHF vOTU-Ub were visualized. Although Se-Met and 
native crystals were obtained under similar conditions and resulted in solutions 
containing two CCHF vOTU-Ub molecules in the asymmetric unit, their differing space 
group symmetries underline the fact that the molecular arrangement of the dimer and the 
crystal lattice differ radically. 
Static Light Scattering of CCHF vOTU and CCHF vOTU-Ub Complex 
To further investigate the oligomeric state of CCHF vOTU-Ub and CCHF vOTU, 
static light scattering was performed. For vOTU, 95.7% of the sample’s molecular mass 
was calculated at 18.7 kDa with a 2% error, confirming that CCHF vOTU is a monomer 
in solution. As for CCHF vOTU-Ub, 72.5% of the sample possessed a monomeric 
complex molecular mass of 27.5 kDa with a 1% error. The remaining 25% of the sample 
was found to possess a molecular weight of 54.2 kDa with a 1% error (data not shown). 
Overall, the results coupled with the differences in lattice arrangement suggest that the 
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Comparison of CCHF vOTU to other OTU superfamily members 
The overall structure of the Ub in CCHF vOTU-Ub is consistent with previous Ub 
structures; however, despite CCHF vOTU’s structure sharing many tertiary elements with 
other structurally elucidated OTUs, several divergent regions are readily apparent(43, 69). 
In keeping with the OTU superfamily, CCHF vOTU’s core is composed of a β-sheet 
surrounded by helices. In CCHF vOTU’s case, five α helices and a 310 helix flank the 
core β-sheet on one side, with three 310 helices on the other (Figure 2.3b). Although 
CCHF vOTU possesses a β-sheet core with surrounding helices, similarities with other 
OTU superfamily members end there. Unlike previous yOTU1 and OTUB1/2 structures 
that possessed a core formed from only five to six β-strands, CCHF vOTU’s β-sheet is 
comprised of seven β-strands arranged as follows: ↓ β2,↑ β6, ↑ β5, ↑ β3, ↓ β4, ↑ β1a, 
Figure 2.3. I222 asymmetric unit of CCHF vOTU-Ub crystal and CCHF vOTU monomer alone. (a) 
Cartoon representation of the I222 asymmetric unit of CCHF vOTU-Ub. Ub is rendered in light green, with 
CCHF vOTU rendered according to its secondary structures: helices in light blue, β-strands in orange, and 
loops in blue. (b) CCHF vOTU monomer labeled according to secondary structure. 
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and ↑ β1 (Figure 2.3b)(37, 42, 43). An additional β-strand, β2a, forming an anti-parallel β-
sheet with a β-strand formed from Ub residues 73 to 75, was also observed (Figure 2.3b). 
A comparison of CCHF vOTU directly to two other OTUs, yOTU1 and OTUB2, 
highlights the structural uniqueness of CCHF vOTU. By employing secondary structure 
matching to align the structures of yOTU1, OTUB2, and CCHF vOTU, four significant 
structurally divergent regions can be identified (Figure 2.4a and b). Region 1 concerns 
the arrangements of β-strands that form the core of each structure. Within that region, 
CCHF vOTU has a two-β-strand extension of its β-sheet formed from the presence of β1 
and β1a. There is no equivalent to CCHF vOTU’s β4, β1, and β1a in OTUB2, whereas 
yOTU1 does have a β1, but this β1 forms against β2 on the other end of the β-sheet core. 
The existence of these extra β-strands in CCHF vOTU requires that CCHF vOTU’s 
polypeptide pass behind the β-sheet, forming a 310 helix prior to forming β2. This loop 
fills in region 2, which is normally occupied by a conserved α6 helix in all known OTU 
superfamily members. The presence of β1 and β1a also sterically forbids CCHF vOTU 
from binding Ub in the same orientation as yOTU1 does (Figure 2.4c and d). The result is 
a 30° twist of CCHF vOTU’s bound Ub in comparison to that of the yOTU-Ub structure. 
These differences in orientation of Ub or its absence in relationship to the core β-sheet of 
CCHF vOTU, yOTU1, and OTUB2 result in differences in the orientation of α3, which 
comprises region 3 and is a component of the Ub binding interface. Last, region 4 
highlights the absence of α helices present in OTUB1/2 but absent in yOTU1 and CCHF 
vOTU. 
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Figure 2.4. CCHF vOTU and CCHF vOTU-Ub comparison to OTUB2, yOTU1, and yOTU1-Ub. (a) 
Divergent-eyed stereo view of CCHF vOTU (orange and blue) aligned with yOTU1 (gray) using secondary 
structure matching though COOT. (b) Divergent-eyed stereo view of CCHF vOTU colored as in panel a 
aligned with hOTUB2 (magenta). (c) Divergent-eyed stereo view of CCHF vOTU-Ub with Ub sourced 
from a secondary structure alignment of CCHF vOTU-Ub and yOTU1-Ub. CCHF vOTU is rendered as a 
cartoon and colored according to secondary structure, with helices in light blue, β-strands in orange, and 
loops in blue. Ub of the CCHF vOTU-Ub complex is also rendered as a cartoon and colored light green. Ub 
from a yOTU1-Ub that was aligned with CCHF vOTU-Ub using the secondary structure matching of 
CCHF vOTU and yOTU1 is rendered as a cartoon in red. (d) Shown is a 180° y-axis rotation of panel c. 
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CCHF vOTU binding interface with Ub  
The 1,065 Å2 of buried surface area between CCHF vOTU and Ub can be 
optimally described by its classification into three areas (Figure 2.5a). One of the two 
most prominent areas of interaction, area I, is comprised of the interface between Ub 
residues 72 to 75, including the propylamine adduct of Ub and numerous residues of 
CCHF vOTU (Figure 2.5b). Four major factors drive the formation of this interface. The 
first of these is the formation of hydrogen (H) bonds between the main chain atoms of Ub 
residues 72 to 75, including the amine in the propylamine adduct, and the main chain 
atoms of CCHF vOTU’s W99, G100, S101, and T150. The overall result of these H 
bonds is the creation of a β-sheet joining CCHF vOTU and Ub. In addition to H-bond 
formation, a network of polar bonds and salt bridges is formed between Ub’s R72 and 
R74 and CCHF vOTU’s E98, E78, and S101. Beyond electrostatic interactions and 
despite the distinctly negative electropotential of area I, a row of CCHF vOTU residues, 
I118, I131, V18, and V12, form a hydrophobic trough deep in CCHF vOTU’s binding 
surface. Part of this trough resides in area I and facilitates a favorable interaction with 
Ub’s L73. The hydrophobic trough continues into another prominent area of interaction, 
area II, with the accommodation of Ub’s V70 and I44. Similar to area I, a network of 
polar bonds and salt bridges is formed between Ub’s E51, Q49, and R42 and CCHF 
vOTU’s R80, E78, P77, and Q16 (Figure 2.5c) in area II. Just as the CCHF vOTU 
hydrophobic trough creates favorable interactions in areas I and II, area III also benefits 
from Ub’s L8 being buried in this trough between CCHF vOTU’s V18 and I131. Also, a 
polar interaction is observed in area III by Ub’s K6 interacting with CCHF vOTU’s N20 
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through a water molecule. Overall, 25 residues from CCHF vOTU and 18 residues from 
Ub are involved in the formation of the interface. Not surprisingly, the 18 residues of Ub 
involved are isolated to one side of the Ub. However, a comparison to Ub bound to 
yOTU1 illustrates that the Ub surface that CCHF vOTU interacts with is not the same as 
that of yOTU1.  
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Figure 2.5. CCHF vOTU-Ub binding interface. (a) Electropotential surface rendering of CCHF vOTU 
generated with the adaptive Poisson-Boltzmann solver (APBS) plug-in of Pymol software(1-4). APBS 
settings were -4 for the negative maximum and 4 for the positive maximum. Ub is illustrated as a light-
green transparent cartoon. Ub residues that reside within 4 Å of vOTU as determined by the use of the 
Contact program part of the CCP4 suite are colored tan(5). Three colored ovals highlight the three regions of 
interactions between CCHF vOTU and Ub: area I (cyan), area II (yellow), and area III (green). (b) Close-up 
of area I with CCHF vOTU rendered in cartoon and stick format with color according to the secondary 
structure: helices in light blue, β-strands in orange, and loops in blue. Ub is also rendered in cartoon and 
stick format but is colored in green. A cartoon view of the secondary structure of residues 70 to 75 in Ub 
has been hidden for clarity. White labels indicate Ub residues, black labels indicate CCHF vOTU, and pink 
labels and dashes indicate distances. All distance numbers are in angstroms. (c and d) Close-up of area II 
and area III, respectively, with CCHF vOTU and Ub colored as in panel b. (e) Surface rendering of a 180° 
x/y-axis rotation of the Ub bound in panel a. In general, Ub is colored light green, with the regions colored 
tan in panel a colored the same in panel b. (f) Surface rendering of Ub from yOTU1-Ub in a similar 
orientation as Ub in panel b. Ub is colored in red, with residues within 4 Å of yOTU1, as determined by the 
use of the Contact program from the CCP4 suite, colored yellow(5). 
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CCHF vOTU’s catalytic triad  
As CCHF vOTU was predicted to be a cysteine protease and only possesses one 
cysteine (C40), research groups were quick to identify it as critical to CCHF vOTU’s 
protease activity. However, identification of the remaining two residues involved in 
CCHF vOTU’s catalytic triad has remained elusive. Recent studies have proposed H151 
of CCHF vOTU as a member of the CCHF vOTU catalytic triad but have only reported 
on activity of the C40/H151 double mutant(39). Additionally, the presence of a histidine at 
the equivalent position of CCHF vOTU’s E98 in the proposed viral OTU subclass 
arterivirus member’s NSP2 proteases has also spurred speculation on the location of the 
catalytic histidine within the viral OTU subclass (39, 70). As for the aspartic acid 
component of the catalytic triad, D37 and D153 have been suggested as candidates(71). To 
clarify the identity of the complete catalytic triad, the active site of CCHF vOTU was 
inspected. Although several CCHF vOTU histidine and aspartic acid residues, including 
H43 and D37, were within the general area of that catalytic cysteine, only H151 and 
D153 were in close enough proximity and in the correct orientation to assist in the 
deprotonation of CCHF vOTU’s C40 (Figure 2.6a). To confirm the essentiality of these 
amino acids, they were mutated to alanine, and the activity of the resulting protein 
containing CCHF vOTU was assessed. CCHF vOTU mutants C40A and W99A exhibited 
an ~1,000-fold loss of Vmax compared to that for wild-type (wt) CCHF vOTU. The CCHF 
vOTU mutant H151A possessed only a slightly higher Vmax than that of CCHF vOTU 
mutants C40A and W99A, with ~350-fold loss of activity compared to that of the wt. The 
most active CCHF vOTU mutant, D153A, was still ~40- fold less active than wt CCHF 
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vOTU. All of the CCHF vOTU mutants exhibited a KM of ~4-fold more than that for wt 
CCHF vOTU (Figure 2.6b).  
 CCHF vOTU’s K63- and K48-linked deubiquitinating activity  
 
To investigate CCHF vOTU’s activity toward both K63- and K48-linked di-Ub 
species, both K63- and K48-linked species of di-Ub were acquired. Cleavage of 10 µM 
di-Ub species by 10 nM CCHF vOTU was monitored over the course of 1 h by their 
products being resolved on a 10 to 20% Ready Gel Tris-Tricine gel and visualized by 
staining with Coomassie blue (Figure 2.7a). Interestingly, there is no difference in CCHF 
vOTU’s activity toward the two di-Ub substrates. To assess whether larger poly-Ub 
species could also be cleaved by CCHF vOTU, K48- and K63-linked tetra-Ub was 
obtained. These tetra-Ub species were cleaved in the same manner as their di-Ub 
counterparts. Unlike the comparable activity between K48- and K63-linked di-Ub 
species, CCHF vOTU appears to have a slight preference for the two tetra-Ub substrates. 
Figure 2.6.	  Active site of CCHF vOTU. (a) Cartoon and stick rendering of CCHF vOTU’s active site. 
CCHF vOTU is colored according to its secondary structures, with helices in light blue, β-strands in 
orange, and loops in blue. (b) Ub KM and Vmax constants for catalytic triad CCHF vOTU mutants. 
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For K63-linked tetra-Ub, almost no poly-Ub species are visible after 10 min, whereas 
several poly-Ub species appear at this time frame, and faint bands can also be seen at the 
60-min time frame in the K48-linked tetra-Ub reactions (Figure 2.7a). 
  
Figure 2.7	  Polydeubiquitination as well as Poly-Ub and CCHF vOTU-ISG15 models. (a) CCHF 
vOTU’s cleavage of K48-linked di-Ub and K63-linked di-Ub (top panel) and K48-linked tetra-Ub and 
K63-linked tetra-Ub (bottom panel). (b) Location of lysine residues on CCHF vOTU-bound Ub. The 
surface of CCHF vOTU is colored blue, with Ub shown as a cartoon in light green. Lysine residues 
located in Ub are colored magenta and labeled accordingly. (c) ISG15 (2JF5) aligned using a 
secondary structure-matching tool in Coot to the Ub bound to CCHF vOTU(5). ISG15 is rendered as a 
cartoon in orange. (d) K63-linked di-Ub (3H7P) and K48-linked di-Ub (2BGF) aligned using a 
secondary structure-matching tool in Coot to the Ub bound to CCHF vOTU(5). K63-linked di-Ub 
rendered as a cartoon in dark blue, with K48-linked di-Ub in purple(6, 7). 
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Discussion 
CCHF vOTU and other viral OTU superfamily members 
In general, viral genomes undergo a higher rate of mutation and recombination 
than their eukaryotic and prokaryotic counterparts. The CCHF virus is no different. 
Interestingly, the L protein tends to be the most conserved among those in the three-
segmented genome, suggesting an evolutionary need to minimize substantive changes in 
the L protein(72). For the L protein itself, the RdRp’s variable region (amino acids 752 to 
851) tends to be the source of most L-protein diversity(73). Intriguingly, this leaves the 
vOTU containing region of the L protein only a few mutations between GenBank entries 
from strains from Kosovo (ABW17160), Turkey (ACT88368), and China (ADD64466) 
(see entry for CCHF vOTU, AAQ98866.2). Of the 16 polymorphic sites in vOTUs from 
different CCHF strains, only three are located at the vOTU-Ub interface: A14D, R80K, 
and E128G. As CCHF vOTU’s R80 is involved in a salt bridge with Ub’s D98, the 
change of arginine to a shorter lysine residue may impact binding (Figure 2.5b). Unlike 
the case for the R80K polymorphism, any impact of A14D and E128G on protease 
activity and its effects on virulence are hard to predict, as these residues have no readily 
apparent side chain interactions in CCHF vOTU-Ub (Figure 2.5c and d). Nairovirus 
homologs of Dugbe and Nairobi Sheep Disease viruses are also very similar, 72 to 76%, 
respectively, to the CCHF virus vOTU. Most of the differences between the nairoviruses 
lay outside the binding interfaces. However, as with other strains of CCHF vOTU, 
differences found at R80 and E128 might suggest that even closely related nairovirus 
homologs might not have the exact same protease specificity or catalytic capacity. 
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Although CCHF vOTU and its nairovirus homologs are highly conserved, other 
vOTU homologs from the arterivirus genus, including PRRSV, show only less than 40% 
similarity with CCHF vOTU. Despite the low sequence similarity in general, the 
elucidation of the CCHF vOTU structure coupled with the analysis of an arterivirus 
PRRSV amino acid sequence allows some insight into possible tertiary features of 
arterivirus vOTUs. One striking example is that regions of higher conservation between 
CCHF vOTU and the PRRSV vOTU homologs are at the same amino acid positions as 
those involved in substrate binding. This suggests that arterivirus vOTUs may possess a 
substrate-binding interface similar to that of PRRSV (Figure 2.1a). In addition, arterivirus 
vOTUs have a high degree of sequence similarity with the region containing the 
catalytically relevant cysteine as well as a shared amino acid motif among OTU 
superfamily members HXD/N, where X is a 5- to 6-member side chain ring containing 
residues. Since this motif now contains the catalytically relevant histidine and aspartic 
acids in a vOTU superfamily member, there is a strong likelihood that the arterivirus 
vOTUs catalytic triad residues also reside in this motif. 
Potential vOTU primary and tertiary structural determinates for substrate 
recognition 
yOTU1 shares only 40% of the amino acids positions that comprise the CCHF 
vOTU-Ub binding interface. This, along with the significant difference in the orientation 
of Ub between the CCHF vOTU-Ub and yOTU1-Ub structures, underlines the potential 
diversity of substrate recognition within the OTU superfamily. Although only through an 
intensive mutagenesis approach will the complete understanding of CCHF vOTU 
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substrate recognition be ultimately known, some likely candidates can be envisioned. 
CCHF vOTU’s R80, E51, and N20 are some of these candidates. As a methionine or 
isoleucine in OTUB2 and yOTU1, respectively, R80 forms a salt bridge with E51 in Ub. 
Interestingly, E51 is also a glutamate in ISG15 but is a glutamine in NEDD8. In the case 
of CCHF vOTU’s E78, this residue creates two salt bridges with R72 and R74 of Ub. As 
R74 of Ub is a leucine in NEDD8 and E78 of CCHF vOTU is a histidine in OTUB2, the 
presence of both of these salt bridges is not likely in CCHF vOTU-NEDD8 or in 
OTUB2-Ub. Last, N20 is located on CCHF vOTU’s unique β1-β1a tertiary element and 
forms a set of polar interactions with Ub’s K9 through a water molecule. This interaction 
should be absent completely in OTUB1/2 and yOTU1. 
In addition to CCHF vOTU’s N20 proposed role in mono-Ub and Ub-like 
recognition, its interaction with K6 of Ub suggests that CCHF vOTU may not be able to 
cleave K6 linked poly-Ub conjugates. Analysis of other lysine side chains in the CCHF 
vOTU-Ub structures also suggests that through steric hindrance, CCHF vOTU may not 
prefer K27- or K11-linked poly-Ub (Figure 2.7b). These side chains are buried within the 
CCHF vOTU-Ub interface. When CCHF vOTU-Ub is used as a scaffold for modeling 
CCHF vOTU-ISG15, CCHF vOTU-K63-linked di-Ub, and CCHF vOTU-K48-linked di-
Ub, the results would suggest that CCHF vOTU might also have difficulty also cleaving 
K48-linked poly-Ub (Figure 2.7b - d). Within the CCHF vOTU-Ub structure, K48 is 
located near CCHF vOTU’s surface, and when the K48 di-Ub NMR structure (2BGF) is 
overlaid, significant steric clashes are observed. Interestingly, CCHF vOTU has only a 
slight preference for K63-linked tetra-Ub over its K48-linked counterpart. Of course, this 
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is in contrast to the slight preference that OTUB1 shows for K48-linked poly-Ub over 
K63-linked poly-Ub(43). Additionally, several di-Ub products are observed when CCHF 
vOTU cleaves K48-linked tetra-Ub, suggesting that K48-linked poly-Ub can adopt a 
conformation that allows vOTU access to its isopeptide bonds. CCHF vOTU’s robust 
activity toward K63-linked poly-Ub is also intriguing, as a cysteine protease from murine 
cytomegalovirus shows a more distinct preference for K48-linked di-Ub over K63-linked 
di-Ub(74). CCHF vOTUs cleavage of K63-linked poly-Ub protein conjugates with rates 
slightly greater than K48-linked tetra-Ub might be reflective of the K63-linked poly-Ub 
quaternary structure being similar to that of ISG15 (Figure 2.7c and d). With K63-linked 
poly-Ub and ISG15 activating and/or stabilizing key antiviral proteins, and K48-linked 
poly-Ub’s proteasome-vectoring attributes, CCHF vOTU activity likely has a significant 
impact on these cellular activities. 
Chapter 2 is in part a reprint of the material as it appears in Capodagli G. C., 
McKercher M. A., Baker E. A., Masters E. M., Brunzelle J. S., and  Pegan S. D. (2011) 
Structural analysis of a viral ovarian tumor domain protease from the Crimean-Congo 
hemorrhagic fever virus in complex with covalently bonded ubiquitin. J Virol, 85(7): 
3621-30. The dissertation author was primary researcher and author of this publication. 
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 Chapter Three: Diversity of Ub and ISG15 Specificity among Nairoviruses' vOTU 
Abstract 
Nairoviruses are responsible for numerous diseases that affect both humans and 
animals. Recent work has implicated the viral ovarian tumor domain (vOTU) as a 
possible nairovirus virulence factor due to its ability to edit ubiquitin (Ub) bound to 
cellular proteins and, at least in the case of Crimean-Congo hemorrhagic fever virus 
(CCHFV), to cleave the Ub-like protein interferon-stimulated gene 15 (ISG15), a protein 
involved in the regulation of host immunity. The prospective roles of vOTUs in immune 
evasion have generated several questions concerning whether vOTUs act through a 
preserved specificity for Ub- and ISG15-conjugated proteins and where that specificity 
may originate. To gain insight into the substrate specificity of vOTUs, enzymological 
studies were conducted on vOTUs from Dugbe, CCHFV, and Erve nairoviruses. These 
studies revealed that vOTUs originating from different nairoviruses display a significant 
divergence in their preference toward Ub and ISG15. In addition, a recently identified 
vOTU from the turnip yellow mosaic tymovirus was evaluated to elucidate any possible 
similarities between vOTUs originating from different viral families. Although 
possessing a similar preference for certain polymeric Ub moieties, its activity toward Ub 
in general was significantly less then those of nairoviruses. Lastly, the X-ray 
crystallographic structure of the vOTU from the Dugbe nairovirus was obtained in 
complex with Ub to reveal structural commonalities of vOTUs originating from 
 
  42 
nairoviruses. The structure suggests that divergences between nairovirus vOTUs 
specificity originate at the primary structural level. Comparison of this structure to that 
originating from CCHFV identified key residues that infer the substrate specificity of 
vOTUs.  
Introduction 
Nairoviruses are negative-sense, single-stranded RNA [ssRNA (-)] viruses 
responsible for numerous diseases in both humans and animals. There are 34 known 
viruses belonging to the genus Nairovirus of family Bunyaviridae. Of these, the tickborn 
Crimean-Congo hemorrhagic fever virus (CCHFV), Dugbe virus (DUGV), and Nairobi 
sheep disease virus (NSDV) have been the most investigated. Although these viruses 
share considerable genomic similarity, their effects on both humans and animals vary 
from mild illness to loss of life. CCHFV, the most lethal to humans, is endemic across 
large swaths of sub-Saharan Africa, southeast Europe, and Asia. Fatality rates for 
CCHFV range from 5 to 33% depending on reported and confirmed case statistics. 
However, some outbreaks, to include the recent ones in India and the Sudan, suggest the 
rates could be up to 70 to 80%(49-52, 75). CCHFV has also been reported to infect sheep, 
goats, cattle, horses, and donkeys in the wild; however, the disease does not manifest in a 
fatal form for these animals(76). Comparatively, infection of humans by NSDV and 
DUGV can cause a febrile illness but no associated fatalities (77, 78). NSDV is found in 
Eastern and Central Africa, and the Asian variant Ganjam nairovirus (GANV) found in 
India has been observed to infect sheep with a mortality of up to 90%, generating 
economic distress within infected areas(78-80). Alternatively, DUGV, which originates 
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from sub-Saharan Africa, has not been found to be fatal for any known species. However, 
DUGV can cause mild febrile illness in species beyond humans, particularly cattle that it 
predominantly infects(81, 82). In addition to these human disease-causing nairoviruses, the 
Erve Virus (ERVEV) from northwest Europe has been implicated as a causative agent in 
human thunderclap headaches. ERVEV was isolated from the white-toothed shrew in 
1982 and classified by indirect immunofluorescence assay (IFA) as belonging to the 
Nairovirus genus, ERVEV has only been recently sequenced limiting previous 
exploration of its proteome (83).  
The genome of nairoviruses is partitioned into three RNA segments: small (S), 
medium (M), and large (L). Surprisingly, unlike other Bunyaviridae family members, the 
nairoviruses’ L segment contains not only a RNA-dependent RNA polymerase but also a 
viral ovarian tumor domain protease homolog (vOTU) (39). As ssRNA (-) viruses, no viral 
protease is required for nairovirus genome replication (40). Instead, nairovirus vOTUs 
have been proposed to be one potential virulence factor(39, 40, 84-86). Unlike the previously 
identified Bunyaviridae family virulence factor, nonstructural protein NSs, which blocks 
transcription of alpha/beta interferon (IFN-α/β) and is absent in nairoviruses, vOTUs are 
suggested to impair innate immunity through deubiquitinating and deISGylating activity 
(87, 88). As a deubiquitinating and deISGylating protease, nairovirus vOTUs fall into one of 
five protease superfamilies that facilitate a myriad of cellular processes such as 
proteasomal degradation, cell division, and regulation of the innate immune response 
through reversal of post-translational modification by ubiquitin (Ub)(89). The multitude of 
outcomes is achieved by Ub’s ability to form polymeric Ub (poly-Ub) chains through 
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Ub’s C-terminal glycine forming either a peptide bond via the N terminus (linear) or an 
isopeptide bond with one of the seven lysines (K6, -11, -27, -29, -33, -48, and -63) of a 
partnering Ub. Each linkage type has been implicated in acting as a specific type of 
cellular signal. The canonical linkages of K48 and K63 poly-Ub were the first studied 
and are associated with proteosomal degradation and induction of the type I IFN (IFNI) 
immune response, respectively(22, 23). In the last decade the more non-canonical and less 
well studied linkages have been tied to lysozomal trafficking (K29), regulation of cellular 
division (K11), and modulation of immunological signaling pathways (K6, K27, and 
K33)(18-21, 90). 
Recent studies have observed divergences in immunological response between 
human cells infected by DUGV and CCHFV underlining the differences in which the 
respective viruses influence cellular immunity(91, 92). Also, this phenomenon has been 
observed between GANV and NSDV. Specifically, Holzer et al. recently narrowed IFN-
α/β suppression to primarily the first 169 amino acids of the L-protein and suggested that 
the vOTU GANV may have less activity than that of CCHFV(93). However, the use of the 
recombinant overexpression system limited the ability to detect the extent of variability in 
deubiquitinating and deISGylating activity between the vOTUs originating from these 
viruses. This limitation has been observed in other studies, where unnaturally high 
expression of vOTUs, or when generously added in vitro, leading to a nearly 1:1 ratio of 
vOTU to Ub or ISG15 substrates, likely masks their specificity for poly-Ub and ISG15 
conjugates, particularly during early viral replication(39, 46, 94). In addition, the increasing 
number of vOTUs being identified in ssRNA (-) and ssRNA (+) viral genomes, including 
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the rice stripe tenuivirus (RSV), turnip yellow mosaic tymovirus (TYMV), and 
arteriviruses such as porcine reproductive and respiratory syndrome (PRRSV), have 
spurred speculation of whether their vOTUs’ specificity and subsequent role is 
conserved(39, 46, 47). 
To gain insight into the variability of deubiquitinating and deISGylating activity, 
the specificity among vOTUs from nairoviruses and how they may compare to non-
nairovirus vOTUs, the enzymatic parameters and specificity of vOTUs from CCHFV, 
DUGV, ERVEV, and TYMV in regards to Ub, poly-Ub, and ISG15 moieties were 
determined. Finally, the X-ray crystal structure of the vOTU from DUGV bound with Ub 
was obtained to assess the potential origins of any detected variability among nairovirus 
vOTUs implicating primary structure as the main source of substrate specificity 
fluctuations. By comparing the structure of vOTUs bound to Ub from DUGV and 
CCHFV, key amino acid positions within nairovirus vOTUs that influenced activity were 
identified. 
Methods 
I thank Keith Wilkinson for his gift of Ub expression plasmids. The Advanced 
Light Source is supported by the Office of Science, Office of Basic Energy Sciences, of 
the U.S. Department of Energy under contract DE-AC02-05CH11231. This study was 
supported with funding provided by National Institute of Health grants 1R03AI092249- 
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Construction of vOTUs and Ub-Br3 expression vectors. 
The production of the vOTU expression construct harboring the 169 amino acids 
from the L protein in CCHFV (CCHF vOTU; GenBank accession no. AAQ98866.2) is as 
previously described(85). The vOTUs from TYMV, ERVEV, and DUGV (TYM vOTU, 
ERVE vOTU, and DUG vOTU) were generated using the Escherichia coli (E. coli) BL21 
codon optimized synthesis by GenScript, Inc. The DUG vOTU gene expression construct 
contained the first 169 amino acids from the L protein of DUGV (GenBank accession no. 
AAB18834.1). For the ERVEV vOTU expression construct, the first 171 amino acids 
from the L protein in ERVEV (GenBank AFH89032.1), which correspond to the first 169 
amino acids of CCHF vOTU and DUG vOTU (Figure 3.1) and includes the OTU domain 
as described by Dilcher et al. were utilized(83). Similarly to the CCHF vOTU construct, 
six histidines and a stop codon were added to ERVE vOTU and DUG vOTU constructs 
to generate a C-terminal histidine tag. For the TYM vOTU expression vector, the 151-
amino-acid vOTU domain (residues 728 to 879) of TYMV (GenBank accession no. 
NP_663297.1) that included the vOTU domain as described in Chenon et al. with a six-
histidine N terminus tag was synthesized(46). DUG vOTU, TYM vOTU, and ERVE 
vOTU were incorporated into pET11a plasmids using NdeI and BamHI restriction sites. 
The vOTU constructs were introduced into E. coli BL21 (DE3) competent cells by heat-
shock transformation. The resulting plasmids were then purified, restriction analyzed, and 
sequenced to verify the construct. Constructs of expression plasmids for truncated human 
Ub to be C-terminally modified with 3-bromopropylamine were designed according to 
previously established studies(43, 60). 
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Figure 3.1. Sequence alignment of several viral OTU proteases. The vOTUs are from Dugbe virus 
(DUGV; GenBank accession no. AAB18834.1), Crimean-Congo hemorrhagic fever virus (CCHFV; 
GenBank accession no. AAQ98866.2), Nairobi sheep disease virus (NSDV; GenBank accession no. 
ACH99799.1), Erve virus (ERVEV; GenBank accession no. AFH89032), rice stripe virus (RSV; GenBank 
accession no. ABC68333), turnip yellow mosaic virus (TYMV; GenBank accession no. NP_663297.1), and 
porcine reproductive and respiratory virus (PRRSV; GenBank accession no. Q9WJB2). The secondary 
structure of DUG vOTU according to Defined Secondary Structure of Proteins (DSSP) is shown as gray 
cylinders (helical regions), pink arrows (β-sheets), and gray lines (loops). Hashed gray line represents 
residues for which electron density was not defined in the crystal structure. Breaks denote regions were 
DUG vOTU does not have residues. Asterisks represent amino acid residues chosen for site-directed 
mutation. Orange brackets indicate residues that are part of vOTUs’ catalytic triad. A yellow bracket 
outlines residues involved in a backbone shift between CCHFV and DUGV. 
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Expression and production of vOTUs and Ub-Br3. 
For vOTU enzymatic studies, E. coli strains harboring vOTUs from CCHFV, 
DUGV, ERVEV, and TYMV were grown at 37°C in 6 liters of Luria-Bertani broth 
containing 100 µg of ampicillin/mL until the optical density at 600 nm reached 0.6. 
Expression of the vOTU gene was induced by the addition of IPTG (isopropyl-β-D-
thiogalactopyranoside) to a final concentration of 0.8 mM. The culture was further grown 
for 4 h at 37°C and then centrifuged at 6,000g for 10 min. The cells were collected and 
stored at -80°C until use. All vOTUs were purified according to the previously published 
protocol(85). All final protein concentrations were determined from the absorbance at 280 
nm using an experimentally determined extinction coefficient(61). 
Truncated human Ub (1-75) was expressed according to previously established 
protocols with the exception that, after the IPTG induction, the culture was grown 
overnight at 18°C(43, 60). E. coli BL21 (DE3)-Codon- Plus pellets containing Ub (1-75) 
were lysed with buffer C (25 mM HEPES [pH 6.8], 50 mM sodium acetate, 75 mM 
NaCl) augmented with 0.16% Triton X-100. The solution was then sonicated on ice at 
30% power with pulses of 5-s durations for 10 min. Insoluble debris was removed by 
centrifugation at 17,000g for 45 min. The clarified extract was filtered with a 0.80-µm-
pore-size filter and then poured over a chitin column pre-equilibrated with buffer C. The 
column was washed with three column volumes of buffer C, followed by resuspension in 
two column volumes of buffer C supplemented with 100mM sodium 2-
mercaptoethanesulfonate (MESNA). The resuspension was rocked gently overnight at 
4°C and eluted by filtration through a XK 26/40 GE column. The resulting Ub thioester 
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was then derivatized with 3-bromopropylamine hydrobromide (Ub-Br3) according to 
previously described methods(43, 60). The purity of the Ub-Br3 was assessed by use of 10 
to 20% Mini-Protean Tris-Tricine precast gels (Bio-Rad, CA). 
Site-directed mutagenesis of the CCHF vOTU and DUG vOTU genes. 
CCHF vOTU T10E, S101G, E128G, and E128T, as well as DUG vOTU E10T, 
G101S, T128E, and α3-chimera (D74Q/T75E/ V80R/G81L/T82V) protein mutants were 
created by using QuikChange site-directed mutagenesis according to the manufacturer’s 
protocol (Agilent Technologies, Inc.). The resulting mutant plasmids were introduced 
into E. coli XL1-Blue Supercompetent cells by heat shock transformation and were then 
propagated, purified for sequence verification, and transformed into E. coli BL21 (DE3) 
cells for enzyme expression. The complete coding regions for all mutant enzymes were 
sequenced by GenScript, Inc., or Eton Bioscience, Inc. 
Fluorescent vOTU deubiquitination and deISGylation assays. 
All assays were performed in duplicate in buffer D (100 mM NaCl, 50 mM 
HEPES [pH 7.5], 0.01 mg of bovine serum albumin [BSA]/mL, 5 mM dithiothreitol 
[DTT]) using a Corning Costar half-volume black 96-well plate with a reaction volume 
of 50 µL. The rates of the reactions were observed using an Infinite M1000 series plate 
reader (Tecan, Inc.). Specifically, the increase in fluorescence (excitation λ, 360 nm; 
emission, 460 nm) of 7-amino-4-methylcourmarin (AMC) upon cleavage from Ub-AMC, 
human ISG15-AMC (hISG15-AMC) (Boston Biochem, MA), and ZRLRGG-AMC 
(Bachem) substrates was monitored for each of the vOTUs. The extinction coefficients 
for all three fluorescent substrates were determined by adding excess vOTU to various 
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concentrations of each substrate, and the reactions were allowed to run until completion. 
The resulting maximum fluorescence values were plotted to determine the slope and 
subsequently each substrate’s extinction coefficient. 
To calculate the turnover rates for 1 µM hISG15-AMC, 1 µM Ub-AMC, and 50 
µM ZRLRGG-AMC of DUG vOTU, ERVE vOTU, and TYM vOTU, as well as mutants 
originating from DUG vOTU and CCHF vOTU, various enzyme concentrations were 
used. This was to account for the varied activities of different vOTUs toward their Ub 
and hISG15 substrates. For DUG vOTU and associated mutants, 2 µM, 4 nM, and 4 µM 
concentrations of enzyme were used against hISG15-AMC, Ub-AMC, and ZRLRGG-
AMC, respectively. The enzyme concentrations for CCHF vOTU and associated mutants 
were the same concentrations as those of DUG vOTU with the exception of 20 nM 
enzyme being utilized to observe the cleavage of hISG15-AMC. Similarly, 4 nM ERVE 
vOTU was used to cleave Ub-AMC and hISG15-AMC, with 1 µM enzyme used to 
cleave 50 µM ZRLRGG-AMC. For TYM vOTU, 2.2, 1.2, and 4 µM concentrations of 
enzyme were used to cleave hISG15-AMC, Ub-AMC, and ZRLRGG-AMC, respectively. 
To determine the DUG vOTU’s Vmax and KM values for Ub-AMC, DUG vOTU’s 
concentration was maintained at 4 nM enzyme while the Ub-AMC concentration was 
varied from 0 to 75 µM. To determine DUG vOTU’s Vmax and KM values for hISG15-
AMC, DUG vOTU’s concentration was maintained at 2 µM enzyme, while the hISG15-
AMC concentration was varied from 0 to 32 µM. For calculation of the Vmax and KM 
values for TYM vOTU, an enzyme concentration of 1.2 µM was used while the Ub-AMC 
concentration was varied from 0 to 65 µM, and an enzyme concentration of 2.2 µM was 
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used while the hISG15-AMC concentration was varied from 0 to 32 µM. ERVE vOTU’s 
Vmax and KM values for Ub-AMC and hISG15-AMC were determined maintaining an 
enzyme concentration of 125 nM while the Ub-AMC concentration was varied from 0 to 
51 µM, and an enzyme concentration of 4 nM was maintained while the hISG15-AMC 
concentration was varied from 0 to 5 µM. The initial rates were fitted to the Michaelis-
Menten equation, ν = Vmax/[1 / (KM/[S])], using the Enzyme Kinetics module of 
SigmaPlot (v12.2; SPSS, Inc.). Vmax was translated into kcat using kcat  = Vmax/[E]. 
The vOTUs from CCHFV, DUGV, ERVEV, and TYMV turnover rates for di-Ub 
Förster resonance energy transfer (FRET) linkage substrates K11, K48, and K63 (Boston 
Biochem, MA) at 1 µM were determined by monitoring the increase in fluorescence 
(excitation λ, 544 nm; emission, 572 nm) resulting by the separation of a FRET 
TAMRA/QXL pair. The cleavage of three commercially available FRET TAMRA/QXL 
pair configurations per K48 and K63 di-Ub linkage FRET substrates was assessed. Each 
di-Ub FRET substrate at 1 µM was evaluated against an enzyme concentration of 2 nM 
(CCHF and DUG vOTU), 125 nM (ERVE vOTU), or 500 nM (TYM vOTU). For the 
K11 di-Ub FRET substrate, enzyme concentrations of vOTUs from CCHFV (100 nM), 
DUGV (100 nM), ERVEV (2.6 µM), TYMV (20 nM) were used. 
Deubiquitinating gel shift assay. 
Poly-Ub linked by the different isopeptide bonds (K6, K11, K27, K29, K33, K48, 
and K63), as well as the N-terminal peptide bond (linear), were purchased from Boston 
Biochem, MA. Dimeric-Ub substrates (10 µM) were incubated with each vOTU (4 nM 
CCHF vOTU, 4 nM DUG vOTU, 100 nM ERVE vOTU, and 6 µM TYM vOTU) in 
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reaction buffer F (100mM NaCl, 50mM HEPES [pH 7.5], 2mM DTT) at 37°C. The 
reactions were stopped at various times of 1 h by mixing 9 µL of each reaction with 2✕ 
sodium dodecyl sulfate-Tricine sample buffer, followed by boiling at 95°C for 5 min. The 
results were visualized on 10 to 20% Mini-Protean Tris-Tricine precast gels (Bio-Rad). 
For vOTU cleavage of trimeric K48 and K63 linkages, 20 µM tri-Ub substrates were 
tested and analyzed in the same manner as the di-Ub. 
DUG vOTU-Ub complex formation and crystallization. 
DUGV vOTU was combined with Ub-Br3 in equal molar ratios, incubated at 
37°C for 2 h and left overnight at 4°C. Complex (DUG vOTU-Ub) formation was 
monitored using 10 to 20% Mini-Protean Tris-Tricine precast gels. DUG vOTU-Ub was 
dialyzed overnight against 1 liter of buffer G (100 mM NaCl, 50 mM Tris-HCl [pH 8.0]) 
and then purified using a GE Mono-Q column with a linear gradient of buffer G to buffer 
H (1 M NaCl, 50 mM Tris-HCl [pH 8.0]). Fractions were pooled according to the 
chromatogram, loaded onto an AP-1 (Waters) column packed with Superdex-75 resin 
pre-equilibrated with buffer I (150 mM NaCl, 5 mM HEPES [pH 7.4], 1 mM TCEP-
HCl), and eluted at a flow rate of 1.0 mL/min. Resulting DUG vOTU-Ub was 
concentrated in a GE Vivaspin 6 10-kDa MWCO concentrator and filtered using a 0.22-
µm-pore-size Costar spin filter. The initial crystal conditions for DUG vOTU-Ub were 
determined from high-throughput screening of Qiagen Classics I and II screens in a 96-
well sitting drop format using an Art Robbins Phoenix robot. Drops contained 0.4 µL of 
protein solution and 0.4 µL of precipitate with a 100-µL reservoir volume. Initial 
screening resulted in several hits; however, a solution containing 0.25 M LiSO4, 0.10 M 
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Bis-Tris (pH 5.5), and 29% PEG 3350 produced the most viable crystals. These crystals 
were optimized using the Additive HT Screen from Hampton Research. Final DUG 
vOTU-Ub crystals were obtained through vapor diffusion using a 500-µL reservoir with 
4-µL hanging drops mixed 1:1 with protein solution and 0.25 µL of 40% (vol/vol) 1,3-
butanediol. 
Data collection and X-ray structural determination of DUG vOTU-Ub. 
An X-ray data set was collected using a crystal mounted onto a nylon loop flash 
frozen in liquid nitrogen. The frozen crystal was mounted under a stream of dry N2 at 100 
K. A DUG vOTU-Ub data set with resolution to 2.85 Å was collected at the advanced 
light source (ALS) beam line 4.2.2 at 1.00 Å with a NOIR-1 MBC detector (NOIR-1). X-
ray images were indexed, processed, integrated, and scaled using HKL2000(62), and 
phases were determined and refined using Phaser(5). An initial phase solution was 
elucidated using a homology model based on the CCHF vOTU-Ub structure 3PRP for 
molecular replacement using Phaser(5). The structure was refined using iterative cycles of 
model building and refinement using COOT and REFMAC, respectively(5, 95). Water 
molecules were added to 2Fo-Fc density peaks of  >1 σ using the Find Water COOT 
program function. The final model was checked for structural quality using the CCP4 
suite programs Procheck and Sfcheck. The data refinement statistics are shown in Table 
3.1. Structure factors and coordinates have been assigned PDB code 4HXD. 
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Table 3.1. Crystallographic data for DUG vOTU-Ub complex 
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Results 
Comparison of nairovirus vOTUs specificity for Ub and ISG15 
To assess whether nairovirus vOTUs have a conserved specificity for both Ub and 
hISG15 conjugates, vOTUs from CCHFV, DUGV, and ERVEV were evaluated for their 
ability to remove 7-amino-4-methylcourmarin (AMC) from the C terminus of 1 µM Ub-
AMC, hISG15-AMC, or a peptide that contains the last five highly conserved amino of 
hISG15 and Ub (ZRLRGG-AMC; Figure 3.2). In addition, the recently identified vOTU 
from TYMV was evaluated along side the nairovirus vOTUs to determine whether the 
activity and specificity of negative single-stranded nairoviruses for these substrates is 
potentially similar to a vOTU from a positive single-stranded RNA virus. Initially, the 
four vOTUs were assessed against the ZRLRGG-AMC conjugate to observe their affinity 
for the minimal recognition component these proteases use to identify Ub and hISG15 
(Figure 3.2a). The vOTUs of ERVEV and TYMV have a substantially more robust 
activity toward this substrate than those of CCHFV and DUGV (Figure 3.2a). As 
observed in our previous study, CCHF vOTU cleaves the Ub-AMC 5-fold faster than its 
Figure 3.2.	  vOTU cleavage of peptide, Ub, and hISG15 AMC conjugates. The cleavage activities of 
vOTUs from CCHFV, DUGV, and TYMV for 50 µM ZRLRGG-AMC (a), 1 µM Ub-AMC (b), and 1 µM 
hISG15-AMC (c) were determined. Error bars represent standard deviations from the average. 
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hISG15-AMC counterpart(85). Unexpectedly, the other three vOTUs have widely 
divergent activities from CCHF vOTU toward these two substrates (Figure 3.2b and c). 
Specifically, CCHF vOTU cleaves Ub-AMC with a turnover rate twice that of DUG 
vOTU, which is the second most active vOTU toward this substrate. However, DUG 
vOTU possesses 200-fold less activity toward hISG15-AMC, suggesting that every 
vOTU may not be able to robustly cleave hISG15 conjugates. Intriguingly, the vOTU 
from ERVEV exhibits the reverse specificity, overwhelmingly preferring hISG15 to Ub. 
Not surprisingly, vOTU from the plant virus TYMV lacks any appreciable activity for 
hISG15, for which a plant homolog has yet to be identified. However, its 3-orders-of-
magnitude-lower activity for Ub-AMC was interesting since there are only three amino 
acid differences, which are not located on the surface, between human Ub and Ub 
originating from the yellow turnip, Brassica napobrassica. Overall, TYM vOTU has 6-
fold higher activity for ZRLRGG-AMC versus Ub-AMC and 30-fold more than hISG15-
AMC. 
To explore the complexities in the affinities of vOTUs for Ub and hISG15, the 
KM and kcat values of the four vOTUs were ascertained for these substrates (Table 3.2). 
DUG vOTU shows a slightly higher kcat than that of CCHF vOTU for Ub-AMC but with 
a substantially increased KM. These results suggest that DUG vOTU can process Ub-
Table 3.2. Kinetic characterization of vOTUs 
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AMC at rates beyond those of CCHF vOTU but appears to possess a weaker affinity for 
the substrate leading it to have a 6-fold reduction in Ub-AMC catalytic efficiency. For 
hISG15-AMC, DUG vOTU possesses 3 orders of magnitude lower kcat and double the 
KM for this substrate compared to CCHF vOTU. As a result, DUG vOTU’s catalytic 
efficiency for hISG15 approaches that of the TYM vOTU, a vOTU that has likely not 
evolved to process this substrate. TYM vOTU’s affinity for Ub-AMC does not appear to 
be particularly robust either, with saturating conditions of the Ub-AMC substrate beyond 
the maximal substrate concentrations achievable. In contrast to both the vOTUs from 
TYMV and DUGV, ERVE vOTU possesses a high level of ability to cleave hISG15 
conjugates with a kcat within the same magnitude and a KM that was half that of CCHF 
vOTU. This translates into ERVE vOTU having the highest catalytic efficiency for 
hISG15 of any known to vOTU. Surprisingly, ERVE vOTU proves to be a poor 
deubiquitinating enzyme by nairovirus standards, to the point where saturating 
concentrations of Ub-AMC are beyond the maximal substrate concentrations currently 
achievable. Using the data available would suggest at least a 4-fold decrease in Ub-AMC 
kcat compared to CCHF vOTU, as well as a KM that is 2-fold that for DUG vOTU and an 
order of magnitude compared to CCHF vOTU. 
Poly-Ub linkage specificity of nairovirus vOTUs 
Since host cellular proteins are found to be bound to chains of ubiquitin (poly-
Ub), the vOTUs of DUGV, CCHFV, and ERVEV were assessed for their ability to 
cleave the eight different linkage types of poly-Ub, K6, K11, K27, K33, K48, K63, and 
linear, side by side. In addition, TYMV vOTU was similarly evaluated to observe 
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whether there was a potentially conserved preference among divergent viral families. 
With the vOTUs of DUGV and CCHFV exhibiting robust ability to separate Ub 
conjugates, only nanomolar quantities were necessary to observe poly-Ub cleavage 
within a 60-min time frame. Conversely, vOTUs from ERVEV and TYMV, which have 
limited activity toward Ub conjugates, require substantial quantities of protease. In the 
case of TYM vOTU, almost equal molar ratios were required to observe substantial 
cleavage (Figure 3.3). Evaluation of the ability for the four vOTUs to sever the eight 
linkage forms between two Ub monomers unexpectedly revealed that all four vOTUs 
possess a relatively clear preference for K6 poly-Ub linkages. Also, between vOTUs of 
DUGV and CCHFV that were assessed at the same protease concentration, DUG vOTU 
appears to process K6 poly-Ub linkages at a faster rate. Interestingly, the four vOTUs 
have a mixed preference for their secondarily preferred poly-Ub linkage substrate. As 
was observed previously, CCHF vOTU appears to favor K63 poly-Ub linkage(85). 
However, the other three vOTUs seem to favor K48 poly-Ub linkages. In addition to 
severing K6, K48, and K63 poly-Ub linkages, all four vOTUs shared a robust preference 
for K11 poly-Ub linkages. The remaining K27, K29, K33, and linear poly-Ub linkages 
proved to be a relatively poor substrate for each of the four vOTUs to various degrees. 
CCHF vOTU appears to be the most selective of the four vOTUs assessed, only 
preferring the aforementioned K6, K63, K48, and K11 poly-Ub linkages (Figure 3.3). 
Minor relative activities toward K33 and K27 poly-Ub linkages were observed for the 
remaining three vOTUs, with ERVE vOTU possibly having some extremely low relative 
preference toward K29 poly-Ub linkages. 
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Figure 3.3. Gel shift assay of vOTU poly-Ub linkage specificity. A 10 µM concentration of each di-Ub 
linkage was incubated with either 4 nM CCHFV, 4 nM DUGV, 100 nM ERVEV, or 6 µM TYMV at 37°C 
for an hour with samples taken at the indicated time points. The samples were heat inactivated at 95°C for 5 
min and then run on a 10 to 20% Mini-Protean Tris-Tricine precast gels (Bio-Rad). The bands were 
visualized by staining with Coomassie blue. 
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Since the relative preference of 
vOTUs from CCHFV, DUGV, ERVEV, 
and TYMV appear to diverge for K63 and 
K48 poly-Ub linkages, a quantitative 
approach was used to understand the 
extent of the differences for these two 
substrates among these vOTUs. 
Specifically, the increase in fluorescence 
upon the vOTU-facilitated separation of a 
TAMRA/QXL FRET pair located between 
two Ub molecules with either K48 or K63 linkages was examined. To minimize the 
possibility of FRET pair interference with vOTU-Ub interactions, separation of three 
different FRET pair configurations for K48 and K63 FRET substrates were observed 
using vOTUs from CCHFV, DUGV, ERVEV, and TYMV (Figure 3.4). The rate for 
FRET pair configuration that is cleaved most efficiency by each vOTU for K48 and K63 
Figure 3.5. vOTU preference for FRET poly-Ub linkage substrates. (a to c) vOTU cleavage activity for 
K48-linked (a), K63-linked (b), or K11-linked di-Ub (c). Turnover values were determined based on the 
increase in emission upon cleavage of 1 µM di-Ub in the presence of the vOTU from CCHFV, DUGV, and 
TYMV. Error bars represent standard deviations from the average. 
Figure 3.4. Evaluation of Di-Ub FRET Pair 
Positions. 1uM of each TAMRA/QXL FRET pair 
attached at different positions on each Ub in the 
dimer was tested with (a) CCHFV, (b) DUGV, (c) 
ERVEV, and (d) TYMV.  Position 1 is shown in red, 
Position 2 in blue, and Position 3 in green. 
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FRET substrates were compared side by side (Figure 3.5a to c). Although CCHF vOTU 
and DUG vOTU demonstrate comparable turnover rates for K48 poly-Ub linkages, 
CCHF vOTU severs K63 poly-Ub linkages at a rate of 7-fold that of DUG vOTU. Also, 
CCHF vOTU’s turnover rate for the K63 FRET substrate is 3.5-fold elevated over that of 
Ub-AMC. DUG vOTU exhibited a similar phenomenon for its preferred K48 FRET 
substrate. This trend of K48 and K63 specificity was also present with the larger tri-Ub 
substrates (Figure 3.6). Not surprisingly, TYM vOTU and ERVE vOTU cleaved these 
poly-Ub linkage substrates poorly, with the two vOTUs having 2 to 3 orders of 
magnitude less activity than vOTUs from CCHFV and DUGV. In addition to K63 and 
K48 FRET substrates, a K11 FRET substrate was subsequently used to gauge the 
cleavage rates of the four vOTUs for K11 poly-Ub linkages. These results generally 
mirrored those observed in the separation of unlabeled poly-Ub linkages substrates and 
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Figure 3.6. Poly-Ub linkage gel shift assay. A 20 µM concentration of each tri-Ub linkage was incubated 
with either 4 nM CCHF vOTU, 4 nM DUG vOTU, 100 nM ERVE vOTU, or 6 µM TYM vOTU at 37°C 
for an hour with samples taken at the indicated minute time points. The samples were heat inactivated at 
95°C for 5 min and then run on a 10 to 20% Mini-Protean Tris-Tricine precast gels. 
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X-ray crystallographic elucidation of DUG vOTU-Ub complex 
Previous structural elucidation of CCHF vOTU by others and our lab suggested 
that CCHF vOTU’s ability to cleave hISG15, which was unexpected for an OTU, was 
primarily the result of the orientation in which CCHF vOTU bound to its Ub or hISG15 
substrate(84, 85, 96). This suggested that vOTUs might, as a class, possess deISGylating 
activity. However, although the vOTUs from DUGV and ERVEV have high amino acid 
similarity to CCHF vOTU, 79 and 68%, respectively, a significant divergence in their 
preference between Ub and hISG15 conjugates was observed. To investigate the potential 
structural origins of these partialities, a covalent complex was formed between DUG 
vOTU and a bromolyated C-terminal Ub. Subsequently, the DUG vOTU-Ub complex 
was screened against several suites of commercially available precipitant screens and 
further optimized via an additive screen resulting in a set of crystal conditions. The initial 
condition contained PEG 3350, Bis-Tris (pH 5.5), and lithium sulfate and was optimized 
with 1,3-butanediol, yielding a 2.85 Å data set in a C2 space group (Table 3.1). 
Structural comparison of DUG vOTU and CCHF vOTU complexes 
Comparison between the structures of DUG vOTU and CCHF vOTU in complex 
with Ub revealed that the two complexes adopted a comparable fold. Similar to CCHF 
vOTU, DUG vOTU is comprised of a core of seven β-sheets flanked by five α-helices 
and three 310-helices with an additional antiparallel sheet, β2a, formed between residues 
100 to 102 of the protease and residues 73 to 75 of the Ub (Figure 3.7a and b). In 
addition, DUG vOTU appears to accommodate Ub in the same manner as CCHF vOTU, 
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suggesting that DUG vOTU employs no overtly tertiary structure rearrangement to 
account for its partiality between Ub and hISG15 (Figure 3.7c). 
Despite their similarities, the overlay of DUG vOTU and CCHF vOTU bound to 
either Ub or hISG15 does highlight two variances between the vOTUs (Figure 3.7d)(85, 
96). One is the β3-4 loop, which encompasses DUG vOTU residues 121 to 126. This loop 
Figure 3.7. Diagram representation of DUG vOTU-Ub. (a) DUG vOTU monomer labeled and colored 
according to secondary structure: helices and loops are indicated in gray, and β-sheets are indicated in pink. 
(b) Complex of DUG vOTU rendered as in panel a, and Ub is rendered in yellow. (c) Overlay of DUG 
vOTU-Ub complex colored as in b, with Ub bound to CCHF vOTU (orange). (d) Overlay of DUG vOTU, 
CCHF vOTU bound to Ub (green, PDP code 3PRP), and CCHF vOTU bound to hISG15 (teal, PDB code 
3PSE) DUG vOTU is as in panel a, with the α3 helix of each structure rendered as loops and boxed in red. 
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has a higher than average B-factor in both structures of vOTUs from DUGV and CCHFV 
and lacks any direct interaction with other parts of the vOTU, or its bound substrate, 
implying that the divergence observed is a result of inherent loop flexibility. This is not 
the case with the second dissimilar region that contains DUG vOTU residues 73 to 85, 
which comprises its α3 helix and surrounding residues. A clear divergence of this region 
in DUG vOTU can be observed compared to that of either comparable regions in CCHF 
vOTU-Ub or CCHF vOTU-ISG15 structures (Figure 3.7d). Interestingly, this region 
forms a considerable interface with Ub in the DUG vOTU structure, as well as one 
between CCHF vOTU bound to Ub and hISG15 (Figure 3.7c). Two driving forces readily 
appear to be responsible for the divergence between the two proteases’ α3 helix. One is 
that DUG vOTU has a glycine at position 81, similar to many other vOTUs, instead of a 
leucine as in CCHF vOTU. The glycine results in breaking the α3 helix secondary 
structure, making DUG vOTU’s α3 helix shorter than the one found in CCHF vOTU. The 
second appears to be the amino acid sequence of this region. CCHF vOTU possesses not 
only a leucine at position 81 but also a valine at position 82. The hydrophobic side chains 
of these two amino acids appear to insert into hydrophobic patches on Ub and internally 
on CCHF vOTU, respectively (Figure 3.8a). 
Primary structural origins of Ub and ISG15 specificity between vOTUs of 
DUGV and CCHFV 
In order to examine the influence of the α3 helix on vOTUs’ ability to cleave 
hISG15 conjugates, several positions within DUG vOTU—Asp74, Thr75, Val80, Gly81, 
and Thr82—were mutated to their corresponding residues in the CCHF vOTU. The 
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resulting DUG vOTU α3 helix chimera has comparable activity to the wild-type DUG 
vOTU enzyme for the small peptide ZRLRGG-AMC, suggesting that the mutations did 
not impact catalytic activity. As expected, the DUG vOTU α3 helix chimera possesses a 
relatively significant increase of 150% activity for hISG15-AMC. Interestingly, however, 
the DUG vOTU α3-chimera’s ability to cleave the Ub-AMC conjugate decreases 
significantly, suggesting other primary structural elements are necessary to confer robust 
deISGylating activity (Figure 3.9d to f). One such region might include Glu128, which in 
CCHF vOTU forms hydrogen bonds with hISG15’s Asn89 and Lys90 (Figure 3.8b). 
However, these bonds are absent in DUG vOTU because the glutamate is replaced by a 
threonine. Introduction of the T128E mutation in DUG vOTU increases the activity 
toward Ub-AMC by 110%, hISG15-AMC by almost 2,000%, and ZRLRGG-AMC by 
160%. Conversely, replacement of this glutamate in CCHF vOTU to a threonine resulted 
in a drop in activity of 40, 75, and 25% for Ub-AMC, hISG15-AMC, and ZRLRGG-
AMC, respectively. In addition, a strain of CCHFV, UG3010, has been isolated from a 
patient in Uganda that contains a glycine polymorphism at position 128(97). The 
introduction of this residue resulted in a mutant that followed the same pattern as the 
threonine mutation but with a greater effect. These results reveal the influence position 
128 plays in determining specificity and activity within vOTUs (Figure 3.9a to c). 
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Figure 3.8. Locations of selective mutagenesis in vOTUs of CCHFV and DUGV. Wall-eyed stereo 
views of the interactions between DUG vOTU (gray/pink) and CCHF vOTU (teal) with Ub (yellow) and 
hISG15 (magenta) for the α3-chimera (a) and residues 128 (b), 100 to 102 (c), and 10 (d) are shown. Gray 
labels indicate CCHF vOTU residues, white labels indicate DUG vOTU residues, black labels indicate Ub 
and hISG15 residues, and red labels and dashed lines indicate distances. All of the distances are measured 
in angstroms. 
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Beyond position 128 in the vOTU structures of CCHFV and DUGV, position 101 
was identified as a potential key residue. The serine at this position in the structure of 
CCHF vOTU partially comprises β2a that forms an antiparallel β-sheet with Ub. In 
addition, Ser101 in CCHF vOTU also forms key H-bonds with the Ub arginine residues 
72 and 74 side chains. However, this position is filled by a glycine in DUG vOTU, 
potentially impeding DUG vOTU’s ability to interact with its Ub and hISG15 substrates 
(Figure 3.8c). When CCHF vOTU’s Ser101 was mutated to glycine, an expected drop in 
activity toward all assessed substrates of 60% was found. Unexpectedly, when Gly101 in 
DUG vOTU was mutated to serine, a reduction in activity by 90% was noticed for all 
substrates, while also resulting in a lower protein expression (data not shown). In vOTUs 
from DUGV, NSDV, and ERVEV, residue 101 is glycine and 102 is serine, whereas 
CCHF vOTU has a serine and threonine at these positions. Upon closer examination of 
CCHF vOTU’s Thr102, it appears to be twisted in relation to the corresponding residue 
in DUGV via a surrounding hydrophobic environment created by Ile118, Ile131, and 
Phe133. This twist results in fixing the orientation of Ser101 in manner that the side chain 
points toward CCHF vOTU’s bound substrate. 
Unlike the structurally revealed differences in the vOTUs of CCHFV and DUGV 
that appear to limit DUG vOTU’s ability to cleave either Ub or hISG15, DUG vOTU 
possesses at least one interaction that enhances deubiquitinating activity absent in CCHF 
vOTU. Specifically, DUG vOTU’s Glu10 forms hydrogen bonds to His68 in Ub and is 
within hydrogen bonding range of Arg87 in hISG15 (Figure 3.8d). Not surprisingly, 
alteration of Glu10 to threonine in DUG vOTU causes decreases of 75 and 60% in Ub-
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AMC and hISG15-AMC activity, while not affecting the overall catalytic activity of the 
enzyme. Also, when the T10E mutation was introduced into CCHF vOTU an increase of 
50% activity toward Ub-AMC is observed. 
  
Figure 3.9.	  Effects of vOTU mutagenesis on vOTU activity toward peptide, Ub, and hISG15 AMC. 
The cleavage activity of mutants of CCHF vOTU (light gray) or DUG vOTU (dark gray) were determined 
at 1 µM against 1 µM Ub-AMC (a and d), 1 µM hISG15-AMC (b and e), or 50 µM ZRLRLGG-AMC (c 
and f). Error bars represent standard deviations from the average. 
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Discussion 
Structural origins of nairovirus vOTU substrate specificity 
The broad divergence in specificity observed between nairovirus vOTUs appears 
to originate predominantly from their primary structure differences. This is based on the 
conserved β-sheet and α-helix tertiary structural scaffold of vOTUs from DUGV and 
CCHFV, their sequence similarity with other nairovirus vOTUs, and the conserved 
manner in which Ub is bound to these two vOTUs. In addition, the DUG vOTU-Ub 
structure implies that although the 30° twist observed between the nairovirus vOTUs and 
bound Ub and other OTU superfamily members is conserved, it does not necessarily 
imply that a nairovirus vOTU may process ISG15 conjugates, at least not human ones(43, 
85, 98). Several key amino acids have been implicated in affecting CCHF vOTU substrate 
specificity. Specifically, mutation of Q16R and P77D were shown to ablate CCHF vOTU 
affinity for Ub and hISG15, respectively(84, 96). However, in spite of these residues being 
conserved in many nairoviruses, DUG vOTU still demonstrates solely deubiquitinating 
activity illustrating that these conserved sites do not solely indicate substrate preference. 
Through the CCHF vOTU-Ub and DUG vOTU-Ub structures, plus selective cross 
mutagenesis between vOTUs from CCHFV and DUGV, the affinity of nairovirus vOTUs 
for Ub or hISG15 appears to be largely synergistic. Specifically, the sequence 
compositions within the α3 helix along with additional favorable amino acids, such as 
Glu128, or other key positions, appear necessary to confer substantial activity toward 
hISG15 between vOTUs from DUGV and CCHFV. Also, residues such as Thr102 in 
CCHF vOTU, which do not directly interact with Ub or hISG15, seem necessary for the 
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positive influence of serine at the preceding position. Inclusion of serine at a similar 
position in DUG vOTU, which lacks a threonine directly preceding it, highlights that, 
although affinity appears to be synergistic, single unfavorable amino acid changes within 
nairovirus vOTUs can have deleterious effects. An additional example of CCHF vOTU 
residue Glu128, which is a glycine in a CCHFV strain, UG3010, exemplifies this point 
by suggesting that even vOTUs that harbor polymorphisms between strains can have 
considerably divergent enzymatic behavior (Figure 3.9). 
Understandably, with only monomeric Ub bound to DUG vOTU-Ub and CCHF 
vOTU-Ub, these structures have limitations in directly revealing any specifics on what 
may drive nairovirus vOTUs to cleave only K6, K11, K48, and K63 poly-Ub linkages or 
accounting for these vOTUs’ greater rates of cleavage of certain linkages over those 
observed for Ub-AMC, such as those observed for CCHF vOTU’s and DUG vOTU’s 
cleavage of K63 and K48 poly-Ub linkages, respectively. Although the precise origins 
surrounding poly-Ub specificity may require additional structural studies, the tertiary 
structural similarities between the vOTUs of DUGV and CCHFV suggests that these 
differences between nairovirus vOTUs are likely primarily structural in nature. 
Nairovirus vOTUs and other vOTUs 
The increasing inclusion of new vOTU members originating across the viral 
genomes other than nairoviruses, including those of arteriviruses, tymoviruses, and 
tenuiviruses, has spurred speculation on whether there is possible conservation of 
functionality among these proteases(39, 46, 99). Supporting this assertion has been the 
sequence similarity beyond the first 20 to 30 equivalent amino acids of nairoviruses and 
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vOTUs originating from these other viruses (Figure 3.1). However, there are substantial 
differences between the four groups of viruses currently known to utilize vOTUs, 
including the necessity for vOTUs to cleave viral polypeptides in ssRNA (-) vOTU-
containing viruses, the location of viral replication complexes within the host cells, and 
whether the host is plant or animal. Intriguingly from a protease prospective, the vOTU 
from the ssRNA (+) tymovirus TYMV has a very low deubiquitinating activity—almost 
3 orders of magnitude less than vOTUs from DUGV and CCHFV for Ub and poly-Ubs—
suggesting that deubiquitinating activity might be secondary to polypeptide cleavage. 
However, TYM vOTU does prefer the same four, K6, K11, K48, and K63 poly-Ub 
linkages to the others, as do nairovirus vOTUs. Unfortunately, vOTUs from arteriviruses, 
such as PRRSV, have not been evaluated against all eight poly-Ub types of linkages, nor 
have their respective rates toward Ub and ISG15 been established, but they have been 
observed to cleave both K63 and K48 poly-Ub linkages(99). This, with previously 
established sequence homology, could suggest arteriviruses may also have activity 
toward K6 and K11 poly-Ubs. 
Potential influence of nairovirus vOTUs specificity on pathogenesis 
A wide array of disease outcomes has been observed for nairovirus infections of 
humans and animals ranging from transient viremia and migraines to mortality(46, 93, 100). 
Previous studies have proposed that vOTUs play a significant role in the ability of 
nairoviruses to evade host immune response through their deubiquitinating and 
deISGylating activities, prompting them to be considered potential virulence factors(39, 84, 
85, 93, 96). This classification suggests that a significant divergence in vOTU activity, or 
 
  73 
specificity, possibly exists between vOTUs from different nairoviruses and potentially 
within species. The evaluation of deubiquitinating and deISGylating activities of vOTUs 
from CCHFV, DUGV, and ERVEV appears to support this assertion. Despite a 
reasonably high sequence similarity between three evaluated nairovirus vOTUs, orders of 
magnitude differences in proteolytic activity between them have been observed for 
different Ub moieties, as well for hISG15 conjugates. Distilling these preferences into 
catalytic efficiencies readily reflects that particular nairovirus vOTUs do not always 
possess robust dual human deubiquitinating and deISGylating functionality with a 
preference for ubiquitinated substrates as the previously studied vOTU from CCHFV 
may have proposed (Table 3.2)(84, 85, 96). Instead, the preference of nairovirus vOTUs 
potentially could be either for ubiquitinated substrates, ISGylated ones, or both. 
Curiously, among the nairovirus vOTUs evaluated, only the one from the often-
human fatal CCHFV has coexisting robust deubiquitinating and deISGylating activities 
related to Ub and hISG15. The vOTUs from DUGV and ERVEV, which have currently 
not been observed to be fatal in humans, only possess substantial activity toward one or 
the other. For ERVE vOTU, the virtually complete amino acid conservation among Ub 
within animals suggests that ERVE vOTU predominantly acts as a deISGylase during 
infection, making it the first known viral protease that is incapable of effectively cleaving 
both monomeric and polymeric Ub conjugates while still retaining strong activity for 
hISG15.  
This unique ability of CCHF vOTU to cleave hISG15 conjugates at relatively 
high rates originally had differentiated CCHF vOTUs from other members of the OTU 
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superfamily and likened CCHF vOTU to a virulence factor of severe acute respiratory 
coronavirus, papain-like protease (PLpro), which also has strong deubiquitinating and 
deISGylating activities(39, 85, 101). However, the PLpro and CCHF vOTU similarities go 
beyond their ability to cleave both Ub and hISG15. CCHF vOTU appears to be unique 
among the three evaluated nairovirus vOTUs for its ability to robustly cleave K63 poly-
Ub linkages, while retaining the comparable ability to cleave K48 poly-Ub, such as is the 
case for PLpro(102). This is in contrast to other known viral deubiquitinases, such as 
herpes virus M48, or vOTUs from other nairoviruses, including DUG vOTU(74). Also, the 
robust specificity for K63 poly-Ub that CCHF vOTU possesses may be of importance 
pathogenically since Bogunovic et al. recently suggested that ISGylation and 
ubiquitination might be redundant in humans for viral infections(103). With certain host 
immunologically related proteins having been observed to be modified with either ISG15 
or K63 poly-Ub, the removal of both by a viral protease may ensure immunosuppression. 
Comparison of CCHF vOTU’s poly-Ub preferences and those of other vOTUs also 
illustrates that CCHF vOTU is also the most specific to the four poly-Ub linkages—K6, 
K11, K48, and K63—that the currently evaluated vOTUs prevailingly cleave (Figure 
3.3). This also likely downplays the need for nairoviruses to cleave these other forms of 
poly-Ub moieties for successful viral evasion. Overall, the substrate preferences of the 
nairovirus vOTUs evaluated here suggest that a virus containing a vOTU capable of not 
only deubiquitinase and species-specific deISGylase activities but also robust 
deubiquitinase activity toward K63 poly-Ub linkages might have the best chance for viral 
immune evasion and pathogenesis. Naturally, the full impact of diversity in specificity 
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among vOTUs on viral pathogenesis can ideally be addressed when a reverse genetics 
system for nairoviruses is available. 
Chapter 3 is in part a reprint of the material as it appears in Capodagli G. C., 
Deaton M. K., Baker E. A., Lumpkin R. J., and Pegan S. D. (2013) Diversity of Ubiquitin 
and ISG15 Specificity among Nairoviruses’ Viral Ovarian Tumor Domain Proteases. J 
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Chapter Four: Summary 
In the previous two chapters I have detailed our findings on the substrate 
specificity of the vOTU protease from several nairoviruses, as well as one tenuivirus. 
Here I will summarize our results and place them into the context of this new class of 
DUB proteases. When the vOTU from CCHF was first studied for its substrate activity, it 
demonstrated the ability to robustly cleave both Ub and ISG15(39). As this was the first 
time this class of enzyme was examined, it lead to speculation as to whether all vOTUs 
possessed such DUB and deISGylating capacity. Our findings clearly show that this is 
not the case, and that even vOTUs from the same family possess unique substrate 
specificities. Although the DUG vOTU and ERVE vOTU maintain a high level of 
sequence homology to CCHF vOTU, DUG vOTU only readily cleaves Ub and ERVE 
vOTU only ISG15. While it is not surprising that a vOTU that would not encounter 
ISG15 would show practically no affinity for the substrate, such as in the case of TYMV, 
it is interesting that there was also limited DUB activity as the sequence homology across 
species of Ub is nearly identical. The ability to discriminate between substrates is even 
further differentiated when one compares each of the vOTUs’ ability to cleave different 
poly-Ub moieties. Our gel shift assays demonstrate how both linkage position (lysine 48 
vs lysine 63) and linkage length (dimeric vs tetrameric) are important in determining 
which target proteins may be affected by each vOTU’s activity. Furthermore, vOTUs 
appear to be able to distinguish ISG15 from different species as in the case of ERVE 
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vOTU, which showed a shift in activity when mISG15 was introduced into the assay 
containing hISG15(104). The reason for the difference in ISG15 recognition likely stems 
from the higher degree of sequence disparity between species, and that a vector for the 
ERVEV has been reported to be the white tooth shrew, whose ISG15 may share more 
sequence homology to mISG15 than hISG15.  
To better understand the reasoning behind the varied activities of the vOTU 
family, two crystal structures were obtained in complex with Ub: one with CCHF vOTU 
and one with DUG vOTU. Although the overall folds of the proteases in these complexes 
share some similarities with other OTU family members, there are several points of 
departure that help explain the variances in substrate specificity. The addition of the β1 
and β1a sheets in the vOTU structures forces a modification in how their substrates bind 
when compared to yOTU and OTUB1/2. Similarly, the altered binding orientation creates 
several different binding interactions with respect to vOTU’s α3-helix and active site. 
Predictably, the secondary structures of both vOTUs were nearly identical when 
compared to each other except for their α3-helix. Recently, the structure of CCHF vOTU 
covalently bound to ISG15 has been solved and was shown to strongly agree with our 
model thus revealing which residues are also involved in ISG15 recognition (Figure 
2.7)(96). The similarity in the two vOTUs’ secondary structure implicates the primary 
structure of each protein as the likely source for the differing proteolytic activity. Our 
site-directed mutagenesis studies validate this assertion as swapping out key residues 
involved at the Ub/ISG15 interface have been discovered to both shift the substrate 
preferences of the vOTUs as well as decrease overall activity. As no single mutation to 
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DUG vOTU brings the activity for either Ub or ISG15 to the same levels as CCHF 
vOTU, it is likely that there exists a synergistic effect on the part of all the residues 
involved in the interface between the vOTUs and their preferred substrate. 
vOTUs have been suggested to be a virulence factor that help their virus evade the 
immune system of the host, although the exact mechanism is not fully understood. The 
data presented here offer credence to this theory and lend some insight as to the possible 
aspects involved. CCHFV has a high mortality rate in humans, yet almost none in any 
other mammals. Not only can its vOTU cleave hISG15 and K63-linked poly-Ub readily, 
it does so preferentially over mISG15 and other Ub linkages. Interestingly, the UG3010 
strain of CCHFV, which has been shown to have lower mortality rates, also has a 
mutation we have shown reduces both ISG15 and Ub cleavage(97). Likewise, DUGV only 
causes minor viremia in all of its hosts, and although its vOTU possesses decent mono-
Ub activity, it has limited K63-poly-Ub and ISG15 activity compared to the vOTU from 
CCHFV. On the other hand, the ERVEV has been suggested to cause thunderclap 
headaches in humans without being life threatening. Although ERVE vOTU has the 
highest ISG15 affinity of vOTUs tested to date, it also shows less specificity than the 
vOTU from CCHFV, and also lacks any appreciable Ub activity. Together these data 
suggest that perhaps the ability to efficiently cleave both ISG15 and K63-linked poly-Ub 
are essential for a virus’s ability to evade the host’s innate immune system.
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Chapter Five: A Noncompetitive Inhibitor for Mycobacterium tuberculosis’s Class 
IIa Fructose 1,6-Bisphosphate Aldolase 
Abstract 
Class II fructose 1,6-bisphosphate aldolase (FBA) is an enzyme critical for 
bacterial, fungal, and protozoan glycolysis/gluconeogenesis. Importantly, humans lack 
this type of aldolase, having instead a class I FBA that is structurally and mechanistically 
distinct from class II FBAs. As such, class II FBA is considered a putative 
pharmacological target for the development of novel antibiotics against pathogenic 
bacteria such as Mycobacterium tuberculosis, the causative agent for tuberculosis (TB). 
To date, several competitive class II FBA substrate mimic-styled inhibitors have been 
developed; however, they lack either specificity, potency, or properties that limit their 
potential as possible therapeutics. Recently, through the use of enzymatic and structure-
based assisted screening, we identified 8-hydroxyquinoline carboxylic acid (HCA) that 
has an IC50 of 10 ± 1 µM for the class II FBA present in M. tuberculosis (MtFBA). As 
opposed to previous inhibitors, HCA behaves in a noncompetitive manner, shows no 
inhibitory properties toward human and rabbit class I FBAs, and possesses anti-TB 
properties. Furthermore, we were able to determine the crystal structure of HCA bound to 
MtFBA to 2.1 Å. HCA also demonstrates inhibitory effects for other class II FBAs, 
including pathogenic bacteria such as methicillin-resistant Staphylococcus aureus. With 
its broad-spectrum potential, unique inhibitory characteristics, and flexibility of 
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functionalization, the HCA scaffold likely represents an important advancement in the 
development of class II FBA inhibitors that can serve as viable preclinical candidates. 
Introduction 
Tuberculosis (TB) is one of the most prevalent infections in the world and a 
leading cause of mortality in developing countries(105). Mycobacterium tuberculosis, the 
causative agent for TB, infections have been estimated by the World Health Organization 
(WHO) at 8.7 million new cases during 2011, with 1.4 million M. tuberculosis-related 
deaths(106). This brings the total number of estimated new cases and deaths over the past 
five years to a staggering 45.6 million and 8.1 million, respectively. Additionally, one-
third of the world’s population is estimated to have latent M. tuberculosis(105). Further 
exacerbating the danger of TB is the considerable rise of TB co-infecting patients with 
HIV. Specifically, individuals infected with HIV are more than 20 times more likely to 
develop active TB and thus be able to rapidly spread the disease(106, 107). The current 
treatment for TB, Directly Observed Therapy, Short Course (DOTS), relies on directly 
observing the administration of a four-drug cocktail over a two-month span with 
continuous two-drug treatments for an additional two−four months(108). 
In recent years, the WHO has estimated that the rate of curing TB with DOTS has 
declined from 95 to 85%(106). A significant factor in this decline, which has thwarted 
intensifying efforts to eliminate TB, is increasing drug resistance. Incidences of 
multidrug-resistant TB (MDR-TB), TB resistant to the two most efficacious TB drugs, 
are on the rise, with 500,000 cases reported in 2011(106). Also, spreading of extensively 
drug-resistant TB (XDR-TB), MDR-TB with additional resistance to almost all known 
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TB drugs, has occurred. As of 2011, XDR-TB has appeared in 84 countries, including the 
United States(106). For MDR-TB, new treatment regimens, including DOTS plus, have 
been initiated but require 18 months of treatment(109). Treatment options for XDR-TB are 
even more limited(109). Also, the practicality of these prolonged pharmacological 
treatments is largely in doubt, as patient compliance difficulties have already been 
encountered during the six-month DOTS treatment(109). 
The absence of an effective treatment for MDR-TB and XDR-TB and the increase 
in the number of active TB cases among HIV patients highlight the need to explore other 
potential TB drug targets. One widely touted potential drug target is M. tuberculosis’s 
sole fructose 1,6-bisphosphate aldolase (MtFBA, EC 4.1.2.13)(110-121). As a class II 
fructose 1,6-bisphosphate aldolase, MtFBA falls into one of two classes of fructose 1,6-
bisphosphate aldolases (FBAs). Both class I and class II FBAs catalyze the reversible 
aldol condensation of dihydroxyacetone phosphate (DHAP) with glyceraldehyde 3-
phosphate (G3P) to form fructose 1,6-bisphosphate (FBP)(122). However, the two enzyme 
classes differ in their mechanism of catalysis and prevalence among species, which has 
made class II FBAs a highly sought after bacterial target for pharmacological 
development. Specifically, class I FBAs utilize a lysine residue to generate a nucleophilic 
enamine from DHAP, whereas class II aldolases utilize a Zn (II) cation to stabilize the 
DHAP enolate intermediate involved in the aldol condensation reaction(119). Also, the 
location of a key amino acid side chain responsible for proton extraction and addition 
significantly differs(119, 123, 124). Beyond the differences in their reaction mechanisms, the 
two classes of FBAs distinctly differ in their distribution among species. Higher 
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organisms such as humans possess only class I FBAs, whereas protozoa, bacteria, fungi, 
and blue-green algae primarily have class II FBAs, with a few possessing both(125-127). In 
other words, selective inhibitors developed for class II FBAs are unlikely to generate 
toxic effects through disruption of the human class I FBA. 
Additionally, the essentiality of class II FBAs within bacteria has been illustrated 
via knockout studies of both Gram-positive and Gram-negative bacteria, including M. 
tuberculosis, Escherichia coli, Streptomyces galbus, Bacillus subtilis, Pseudomonas 
aeruginosa, Streptococcus pneumoniae, and Candida albicans(115, 119, 128-136). Although 
bacteria such as E. coli and other autotrophic prokaryotes possess both class I and class II 
FBAs, class I FBAs are only conditionally expressed, with class II FBAs being 
essential(115, 120, 137, 138). Beyond knockout studies and MtFBA being the only FBA in M. 
tuberculosis, MtFBA has been observed to be more abundantly produced and/or secreted 
by M. tuberculosis when placed in hypoxic conditions similar to those found within 
necrotic pulmonary lesions where M. tuberculosis resides(111, 121). A p-blast search also 
illustrates that MtFBA is 100% conserved across all sequenced strains of M. tuberculosis, 
including XDR-TB strain KZN605 as well as MDR-TB strain KZN1435. Taken together, 
the essentiality of class II FBAs and the absence of a human homolog have placed class II 
FBAs among the top potential bacterial drug targets currently lacking a viable preclinical 
drug candidate. 
Naturally, as the essentiality of class II FBAs in bacteria was revealed in 2003, 
efforts began in earnest to develop class II FBA inhibitors for use as treatments related to 
TB and other bacterial and protozoan infections(115). The first generation of these 
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inhibitors began with the candidacy of a DHAP analogue, phosphoglycolohydroxymate 
(PGH) that was first reported in 1974(113). Although PGH inhibits class II FBAs through 
competitive inhibition by mimicking DHAP, PGH is extremely promiscuous, inhibiting 
several mammalian enzymes, including class I FBAs(112, 139, 140). Recent attempts to 
follow up on the competitive substrate mimicry approach utilized the chemical skeleton 
of FBP and focused on zinc−inhibitor interactions to gain greater specificity. Although 
low-micromolar, selective competitive inhibitors were observed for MtFBA and other 
bacterial class II FBAs, all of the inhibitors relied on the presence of one or two 
phosphate groups for selectivity and affinity(110, 112, 113, 116, 117, 125, 141). Not surprisingly, 
with the presence of the highly charged phosphate moiety that likely interferes with 
transport across the cell membrane, only one of these substrate mimic-styled inhibitors 
has a measurable minimal inhibitory concentration (MIC) despite them being assessed up 
to 1 mM(110, 112, 113, 116, 117, 125, 141). This sole exception is FBP analogue TD3 that possesses 
a 40 nM affinity for MtFBA. However, despite a recent attempt to validate or optimize 
TD3, no inhibitory effect on M. tuberculosis growth was observed, illustrating the limits 
of these types of inhibitors (110, 112). 
Recently, we identified a chemical scaffold, 8-hydroxyquinoline- 2-carboxylic 
acid (HCA), through the use of enzymatic and structure-based assisted screening that 
allows for selective, druglike, low-micromolar, noncompetitive inhibition of M. 
tuberculosis class IIa FBA as well as those from other pathogenic bacteria. To elucidate 
the in vitro characteristics of the interaction between HCA and MtFBA, the ability of 
HCA to inhibit MtFBA at multiple concentrations was examined, and isothermal titration 
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calorimetry (ITC) was performed. Finally, an X-ray crystal structure of HCA bound with 
MtFBA was elucidated to 2.1 Å and compared to the apo and substrate-bound forms of 
MtFBA. 
Methods 
This research was supported in part by grants from the Professional Research 
Opportunities for Faculty, the Colorado Center for Drug Discovery, Cancer Center 
Support Grant P30CA046934, and the Regis University Research and Scholarship 
Council. The Advanced Light Source is supported by the Director, Office of Science, 
Office of Basic Energy Sciences, of the U.S. Department of Energy under Contract DE-
AC02-05CH11231. 
I thank Mrs. Victoria Jones for her help with determination of MICs as well as Dr. 
Alexander Mankin (University of Illinois, Chicago, IL) for generously providing 
expression vector pCA24n-fbaA harboring the fbaA gene from E. coli K-12. Also, Dr. 
Den R. Tolan (Boston University, Boston, MA) for generously donating the Sigma-
Aldrich rabbit class I FBA. 
Production and Purification of FBAs 
The construction of the M. tuberculosis pET17b-fbaH expression vector harboring 
the fba gene (Rv0363c) was performed as previously described(119). The pET-fbaH 
plasmid was introduced into E. coli BL21 (DE3) by heat-shock transformation for 
enzyme expression. The resulting plasmid was then purified, restriction analyzed, and 
sequenced to verify the construct. The expression system produced a C-terminal, His-
tagged fusion protein, which is herein termed MtFBA. Cells containing MtFBA were 
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grown in 12 L of Luria Broth (LB) broth containing 100 µg/mL ampicillin until an OD at 
600nm of 0.6 was reached. Expression of the fbaH gene was induced by addition of IPTG 
(isopropyl-β-D-thiogalactopyranoside) to a final concentration of 0.4 mM, and the culture 
was grown for an additional 4−6 h at 25 °C. Following this period, the bacterial cells 
were isolated via centrifugation at 3000g for 10 min and stored at −80 °C. The cell pellets 
were suspended in buffer A (300 mM NaCl and 50 mM Tris [pH 8.0]) and lysed by 
addition of 5 mg of chicken lysozyme followed by sonication. The insoluble cell debris 
was separated via centrifugation for 45 min at 17000g. MtFBA was purified from the 
resulting supernatant by using a Qiagen Ni-NTA column and eluted with buffer A 
containing 300 mM imidazole followed by buffer exchange into buffer B (100 mM NaCl, 
20 mM Tricine [pH 8.0], 2 mM dithiothreitol [DTT], and 0.1 mM ZnCl2) by passage over 
a Superdex-S200 High Resolution column. The purified MtFBA was concentrated to 16 
mg/mL via 10000 molecular weight cutoff centrifugal filter units (Millipore Cork, IRL) 
at 4000g. The final protein was then filtered through 0.22 µm Costar spin filters. 
The production of the FBA expression vector for a methicillin resistant strain of 
Staphylococcus aureus (SaFBA) was generated using E. coli BL21 optimized synthesis 
by Genscript, Inc. The SaFBA expression construct encodes the 289 amino acids from 
UniProtKB entry Q5HE75.1 as well as six histidines and a stop codon to generate a C-
terminal histidine tag and incorporated them into pET11a plasmids using NdeI and 
BamHI restriction sites. Transformation, expression, and purification were performed in a 
manner similar to that of MtFBA. 
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The E. coli K-12 class II FBA was obtained from the ASKA library in a pCA24n-
fbaA expression vector harboring the fbaA gene(142). Transformation, expression, and 
purification were performed in a manner similar to that of MtFBA with the exception that 
25 µg/mL chloramphenicol was used in place of ampicillin.  
FBA purified from rabbit muscle was obtained as an ammonium sulfate 
suspension from Sigma-Aldrich (catalog no. A8811). The suspension was spun down at 
13000g for 10 min at 4 °C, the supernatant discarded, and the pellet resuspended in buffer 
B supplemented with 1 mM EDTA. The resuspended protein was centrifuged again at 
3000g for 15 min to remove any solids that remained. 
Recombinant human aldolase-A was purchased form Gen-Way Biotech, Inc., at a 
concentration of 1 µg/µL in buffer C (20 mM Tris-HCl [pH 8.0], 100 mM NaCl, and 20% 
glycerol). 
All protein concentrations were determined through UV−visible spectroscopy at 
280 nm using molar extinction coefficients experimentally derived by the method of Gill 
and von Hippel(61). 
FBA Enzymatic FBP Cleavage Assays 
The activity of FBAs was monitored through a fluorescence-based assay 
measuring the increase in fluorescence due to conversion of resazurin to resorufin via 
diaphorase when coupled with the oxidation of NADH to NAD+. The assay mixture (final 
volume of 50 µL) contained 0.4 mM NAD+, 8 units/mL rabbit glycerol-3-phosphate 
dehydrogenase (GAPDH), 0.01% (w/v) bovine serum albumin (BSA), 2 mM DTT, 15 
mM NaH2AsO4, 100 mM Tris HCl (pH 7.8), 100 mM CH3COOK, 180 nM MtTPI, 1 
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unit/µL diaphorase, and 50 µM resazurin. Triton X-100 was included at a final 
concentration of 0.01% in follow-up assays to identify any promiscuous inhibitors. For 
FBAs derived from M. tuberculosis and E. coli, a final assay concentration of 4 nM was 
used. For FBAs derived from S. aureus, rabbit, and human, a final assay concentration of 
40 nM was used. The reaction was initiated via the addition of FBP at an assay 
concentration of 75 µM. All assays were performed at room temperature and in duplicate 
using Costar 96-well half-area, black flat-bottom polystyrene plates (Corning). All FBA 
activity assays were conducted using a TECAN M1000 plate reader by measuring the 
fluorescence of resorufin at 585 nm when it was excited at 535 nm. A standard curve for 
FBP conversion was determined by adding excess MtFBA to various concentrations of 
FBP and allowing the reactions to run to completion. The resulting maximal fluorescence 
values were plotted to determine the slope and subsequently the conversion factor. 
The IC50 value for the inhibition of MtFBA by HCA was determined at HCA 
concentrations ranging from 0 to 100 µM, with the FBP concentration held constant at 75 
µM. The percent inhibition (I%) was calculated using the formula I% = [1 − (νsample − 
νnegative control)/(νpositive control − νnegative control)] × 100. The resulting I% values were fit via 
nonlinear regression to the equation I% = I%max/(1 + IC50 / [HCA]) using the Enzyme 
Kinetics Module of SigmaPlot, version 12.2 (SPSS, Inc.). 
To determine the mode of action of HCA, inhibition studies were conducted using 
HCA concentrations ranging from 0 to 25 µM with four additional concentrations of FBP 
ranging from 9 to 150 µM used to initiate the reaction. Initial velocity data were fit using 
nonlinear regression analysis to each of the equations describing partial and full models 
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of competitive, uncompetitive, noncompetitive, and mixed inhibition using the Enzyme 
Kinetics Module of SigmaPlot. On the basis of the analysis of fits through “goodness-of-
fit” statistics, the full noncompetitive inhibition model was determined with the equation 
ν = Vmax/[(1 + [I]/Ki) × (1 + KM/[S])], where [S] = [FBP], [I] = [HCA], and Ki is the 
constant for dissociation of HCA from free MtFBA. 
The class II FBAs from E. coli (4 nM) and S. aureus (40 nM) as well as the class I 
FBAs from rabbit muscle (40 nM) and human muscle (40 nM) were tested with a final 
HCA concentration of 25 µM. The reaction was initiated with 75 µM FBP, and I% was 
calculated as previously described. 
Isothermal Titration Calorimetry (ITC) Experiments  
The ITC experiments were performed in duplicate using a NanoITC system (TA 
Instruments, Lindon, UT). MtFBA was dialyzed overnight at 4 °C against buffer D (100 
mM NaCl, 20 mM Tricine [pH 8.0], and 2% Dimethyl sulfoxide [DMSO]). HCA and 
ZnCl2 were dissolved using the buffer in which MtFBA was dialyzed to concentrations of 
5 and 10 mM, respectively. To assess the interaction between HCA and free zinc (II) ion, 
a solution of 5 mM HCA was titrated into 0.4 mM ZnCl2. To assess the interaction 
between HCA and MtFBA, equal portions of 5 mM HCA and 10 mM ZnCl2 were mixed 
and the HCA/ZnCl2 mixture was titrated into 0.25 mM MtFBA. ITC runs were performed 
at 25 °C and comprised of one injection of 1 µL followed by 24 injections of 2 µL for a 
total of 25 injections. Each injection was spaced 200 s apart. The average heat released 
for the last five injections was used to correct for the heat of dilution. Data sets were 
analyzed with NanoAnalyze and fit to an independent model. 
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Inhibitor Susceptibility Testing 
MIC values in 7H9-ADC-Tween 80 broth at 37 °C against M. tuberculosis 
H37Rv (avirulent strain mc26206) were determined using the resazurin blue assay and by 
visually scanning for growth(143). 
Crystallization of the MtFBA-HCA Complex 
Initial crystallization conditions for the substrate-less, zinc-bound holo-MtFBA 
were achieved using conditions from our previously described protocols(119). The final 
crystal was grown using hanging-drop vapor diffusion at 20 °C. Crystallization drops 
included 2 µL of a 16 mg/mL MtFBA protein solution containing buffer B mixed in a 1:1 
ratio with 26% Polyethylene Glycol (PEG) 300, 0.1 M sodium acetate (pH 4.5), and 2% 
DMSO. After 4 weeks, the holo crystal was removed from the hanging drop, placed in 5 
µL of a soaking solution containing 2.5 mM HCA, 26% PEG 300, 0.1 M sodium acetate 
(pH 4.5), and 2% DMSO for 1 h, and then flash-cooled in liquid nitrogen.  
X-ray Structure of the the MtFBA−HCA Complex 
An X-ray data set was collected using a crystal mounted onto a nylon loop flash-
cooled in liquid nitrogen. The crystal was mounted under a stream of dry N2 at 100 K. An 
MtFBA−HCA complex data set with resolution to 2.10 Å was collected at Advance Light 
Source (ALS) beamline 4.2.2 using a monochromic X-ray beam of 1.00 Å with a NOIR-1 
MBC detector. X-ray images were indexed, processed, integrated, and scaled using 
HKL2000(62). An initial phase solution was elucidated using holo-MtFBA [Protein Data 
Bank (PDB) entry 4DEF] as a starting model for molecular replacement using Phaser(5). 
The structure was refined using iterative cycles of model building and refinement using 
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COOT and phenix.refine, respectively(66, 67). Water molecules were added to 2Fo − Fc 
density peaks of  >1σ using the Find Water COOT program function. The final model 
was checked for structural quality using the CCP4 suite programs Procheck and Sfcheck. 
The data refinement statistics are listed in Table 5.1. 
Modeling Missing Loops into the Structure of the MtFBA−HCA Complex 
Residues 167−177 and 210−223, which were unresolved in the X-ray crystal 
structure of MtFBA bound to HCA, were modeled in using MODELER 9v11 under 
default settings and the known sequence of MtFBA(144). Five models were generated and 
inspected in PyMOL, and the final model was chosen by molpdf score.  
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Table 5.1. Data Collection and Refinement Statistics for the MtFBA−HCA Complex 
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Results 
Identification of HCA as an Inhibitor of MtFBA 
Seeking an alternative to the substrate mimic-styled inhibitors that lack several 
qualities thus limiting their potential as viable preclinical leads for MtFBA and other 
class II FBAs, we adopted a fragment-based strategy. This strategy focused on 
enzymatically screening chemical moieties that would simulate the enolate transition 
state’s hydroxamic acid of PGH with MtFBA’s active site Zn (II) but be devoid of groups 
that would interfere with pharmaceutical development. This set of compounds included 
several heterocyclic zinc binding groups that were used to screen for matrix 
metalloprotease inhibitors(145-150). 
Utilizing an assay that coupled MtFBA activity with M. tuberculosis’s 
triosephosphate isomerase (TPI), rabbit glycerol-3-phosphate dehydrogenase (GAPDH), 
and diaphorase for a fluorescent output, 60 small molecules were screened in duplicate at 
a concentration of 1 mM. In addition to using a fluorophore that excited and emitted at 
wavelengths of >500 nm to prevent false positives, the assay also included DTT as well 
as BSA to ward off promiscuous inhibition(151, 152). This small, low-throughput screening 
campaign revealed that 8-hydroxyquinoline-2-carboxylic acid (HCA) reduced MtFBA 
activity more than 95% at a concentration of 1 mM. 
Although several measures were taken to ward off promiscuous inhibition within 
the screening assay and reduce false positives, additional validation steps were conducted 
to further support HCA as an MtFBA inhibitor. Addition of Triton X-100, a known 
disruptor of aggregation-based inhibition, was introduced to test for any promiscuous 
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inhibition, with no alteration in potency observed (Figure 5.1a)(151). Despite the coupling 
enzymes already being in >40-fold excess, to further rule out the possibility that HCA 
was inhibiting a coupling enzyme instead of MtFBA, a 160-fold excess of each coupling 
enzyme was added and assessed at a HCA concentration of 25 µM (Figure 5.1a). No 
ablation of HCA inhibition was observed; suggesting HCA’s effect on the assay was 
linked specifically to MtFBA inhibition. Also, as expected, no HCA-facilitated inhibition 
of the assay was detected when MtFBA’s assay products DHAP and G3P were 
substituted for MtFBA. Understandably, there have been numerous reports of compounds 
possessing 8-hydroxyquinoline moieties acting as promiscuous chelating agents(147, 153, 
154). To test this possibility, a 2-fold increase in the level of Zn (II) was used to determine 
if HCA was indirectly inhibiting MtFBA activity by sequestering Zn (II) in solution. If 
HCA was limiting MtFBA’s access to Zn (II), or stripping MtFBA of Zn (II), an increase 
in the level of Zn (II) should reduce the inhibitory effects of HCA on MtFBA activity. 
Unexpectedly, the potency of HCA for MtFBA slightly increased (Figure 5.1a). A 
Figure 5.1. Kinetic studies of HCA’s inhibition of MtFBA. (a) HCA (25 µM) was tested for its ability to 
inhibit MtFBA activity in the presence of 50 µM ZnCl2, 0.01% Triton X-100, and a 160-fold excess of 
coupling enzymes GAPDH, diaphorase, and MtTPI or FBP products G3P and DHAP (75 µM). The dashed 
line is drawn from the control of 25 µM HCA to aid in comparison. Error bars represent the standard 
deviation from the average. (b) Plot of HCA concentration in the presence of a 2-fold excess of ZnCl2 as 
the HCA concentration was varied from 0 to 100 µM using the Michaelis−Menten equation to determine 
the IC50. (c) Lineweaver−Burke plot of inhibition of MtFBA by HCA. Concentrations of HCA in the 
presence of a 2-fold excess of ZnCl2 were (●) 0, (○) 1.625, (▼) 3.125, (▽) 6.25, (■) 12.5, and (□) 25 µM. 
Data were globally fit to a pure noncompetitive inhibition model. 
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dose−response relationship of HCA and MtFBA conducted under these conditions 
yielded an IC50 of 10 ± 1 µM (Figure 5.1b). Importantly, HCA inhibited the growth of M. 
tuberculosis in 7H9-OADC broth at a concentration of 0.6−1.2 mM. 
Biochemical and Biophysical Properties of the MtFBA−HCA Interaction 
To characterize the nature of the inhibition of MtFBA by HCA, kinetic studies 
and ITC experiments were conducted. To understand the mechanism of inhibition of 
MtFBA activity by HCA, five different FBP concentrations and six different HCA 
concentrations were utilized to determine the kinetic response of MtFBA to varying 
concentrations of substrate and inhibitor. Surprisingly, only the Vmax of MtFBA was 
significantly affected over a 20-fold increase in inhibitor concentration, whereas the KM 
remained constant (Figure 5.1c). This along with using nonlinear regression analysis 
indicated that HCA acts in a noncompetitive manner against FBP with a Ki of 12 ± 1 µM, 
instead of a competitive manner like previously characterized class II FBA inhibitors. 
Next, as HCA is known to bind to zinc (II), the biophysical binding characteristics of 
HCA and free zinc (II) in solution were analyzed via ITC. This revealed an exothermic 
binding event with the following values: Kd = 9.39 ± 0.79 µM, ΔH = −26.8 ± 0.3 kJ/mol, 
ΔS = 6.9 ± 0.9 J mol−1 K−1, and n = 1.86 ± 0.10 (Figure 5.2a). The binding stoichiometry 
of HCA and free zinc (II) in solution determined by ITC matches current X-ray 
crystallography data for the structure of HCA bound to free zinc (II), which also showed 
HCA and zinc (II) interacting in a ratio of 2:1(153). Intriguingly, the data from the 
enzymatic assay showed that HCA’s inhibitory effects against MtFBA are not reduced in 
the presence of a 2-fold excess of ZnCl2. Therefore, to assess the thermodynamic factors 
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that may favor HCA’s interaction with MtFBA versus free zinc (II), HCA was first 
combined with a 3-fold excess of ZnCl2 required for the formation of the HCA−free zinc 
(II) complex and then titrated into MtFBA. As Pegan et al. and de la Paz Santangelo et al. 
recently reported that zinc (II) has to be in solution for the active site of MtFBA to be 
fully occupied, the presence of excess zinc (II) ensured full occupancy(111, 118). In 
addition, the excess zinc allows for the observation of thermodynamic contributions 
outside of HCA−zinc (II) binding events whether with free zinc (II) in solution or the 
active site zinc of MtFBA. Interestingly, the binding profile of HCA with excess ZnCl2 in 
MtFBA differed from that of HCA and free zinc (II), resulting in the following values:  
Kd = 70.8 ± 2.7 µM, ΔH = −66.0 ± 1.0 kJ/mol, ΔS = −141.9 ± 3.2 J mol−1 K−1, and n = 
0.96 ± 0.01 (Figure 5.2b). This suggests that additional enthalpic forces are present 
within the interaction between HCA and MtFBA and may be responsible for HCA’s 
ability to inhibit MtFBA in a direct manner.  
Figure 5.2.	  ITC binding of MtFBA with HCA. The top panel represents the raw heat data from 25 
injections at 25 °C, and the bottom panel shows the integrated heat peak areas plotted vs the molar ratio of 
(a) HCA to ZnCl2 or (b) HCA in the presence of excess ZnCl2 to MtFBA. The last five data points were 
averaged for the heat of dilution and subtracted from the rest of the data. The lines represent the best fits to 
an independent mode. This figure was generated using the NanoAnalyze software provided by TA 
Instruments. 
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Determination of the Structure of HCA Bound to MtFBA 
With the biochemical data proposing that HCA acts in a manner unlike that of 
current class II inhibitors of MtFBA, the X-ray crystallographic structure of HCA bound 
to MtFBA (MtFBA−HCA) was sought. Utilizing previous techniques to generate MtFBA 
in its zinc (II)-bound but substrate-less (holo-MtFBA) form, these crystals were soaked in 
HCA(118). A crystal structure of these HCA-soaked crystals was subsequently resolved to 
2.1 Å (Table 5.1). Not surprisingly, the single monomer in the asymmetric unit globally 
mirrored the TIM barrel fold of previous MtFBA structures and formed a tetrameric 
biological assembly with monomers from adjoining asymmetric units (Figures 5.3 and 
5.4a). However, unlike the fully elucidated MtFBA−PGH structure that possessed density 
for the entire protein, two regions lacked electron density in the MtFBA−HCA structure 
(Figure 5.4a,b). One of these regions is the highly flexible active site loop comprised of 
amino acids 167−177, which contains Glu169 required for the deprotonation−protonation 
step of the MtFBA-facilitated reaction(118). The absence of this loop was not particularly 
shocking as it has been resolved in only one class II FBA structure, that of MtFBA bound 
to PGH(118). Conversely, the second region of MtFBA missing electron density, which 
encompassed the β6α6 loop containing residues 210−223, was unusual. This loop forms 
part of the substrate pocket and contains His212, whose imidazole side chain is involved 
in coordinating the active site Zn (II) ion and can be considered the zinc binding loop [Z-
loop (Figure 5.4c)](118). 
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Figure 5.3. Sequence alignment of class II FBAs and X-ray structure of MtFBA in complex with 
HCA. (a) FBAs are from M. tuberculosis (M. tuber; NP_334786), E. coli (E. coli; PDB entry 1B57_A), 
Yersinia pestis (Y. pestis; ZP_04518851), S. aureus (S. aureus; Q5HE75), Bacillus anthracis (B. anthrac; 
PDB entry 3Q94_A), and Klebsiella pneumoniae (K. pneum; ZP_14594173). The secondary structure of 
the MtFBA−HCA complex according to Defined Secondary Structure of Proteins (DSSP) is shown as 
orange cylinders (helical regions), blue arrows (β-sheets), and orange lines (loops). Dashed lines represent 
residues for which electron density was not defined in the crystal structure. Breaks denote regions where 
MtFBA does not have residues. Black brackets indicate residues that are part of MtFBA’s active site. (b) 
Cartoon rendering of the MtFBA−HCA protomer. Helical regions are represented as cylinders and β-
strands as arrows. Helices and loops are colored orange and β-strands blue; HCA is shown as pink sticks, 
and zinc ion is shown as a black sphere. (c) Same MtFBA−HCA complex shown in panel b but overlaid 
with the MtFBA−PGH complex (PDB entry 4DEL) colored gray. Residues 167−177 (green) and 210−223 
(red) for which density is observed in the MtFBA−PGH structure but not in the MtFBA−HCA structure. 
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Figure 5.4. Rearrangement of the substrate pocket caused by HCA binding. (a) Surface rendering of 
the MtFBA−HCA complex as its tetrameric biological assembly with one MtFBA protomer colored 
orange, the rest colored various shades of gray, and HCA rendered as pink sticks. Loops that were modeled 
in due to a lack of electron density are shown as transparent surfaces and either green sticks (residues 
167−177) or blue sticks (residues 210−223). (b) Close-up of the substrate binding pocket of the 
MtFBA−HCA complex. (c) Close-up of the substrate binding pocket for MtFBA (white) bound with linear 
fructose 1,6-bisphosphate (cyan sticks; PDB entry 3ELF), in which residues 210−223 are colored light 
blue. In all cases, the zinc ions are rendered as a black sphere. 
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Subsequently, closer inspection of the region where the Z-loop would typically 
reside, as well as the active site, readily revealed Fo − Fc density of HCA coordinating the 
MtFBA’s active site Zn(II) in a trident manner (Figure 5.5a and 5.6). Intriguingly, instead 
of accessing the active site Zn (II) through the highly polar and narrow substrate pocket 
of MtFBA, HCA appears to alter the active site. Specifically, it displaces the His212’s 
imidazole side chain for the bound Zn (II). This creates a hydrophobic pocket that 
accommodates the bicyclic structure of HCA (Figure 5.5b). In addition to the 
displacement of His212, Val165, which is located on the flexible active site β5α5 loop, is 
also supplanted by HCA (Figure 5.5b)(118). Although the X-ray data showed clear density 
for Val165, its position was shifted away from the active site. Beyond these alterations 
with the MtFBA active site, HCA forms three coordination bonds with Zn (II). As 
observed in previous MtFBA structures, two additional coordination bonds are formed 
between Zn (II) and histidine residues located at positions 96 and 252. Together, these 
interactions yield a coordination number of 5 (T5) for the active site Zn similar to that of 
the PGH bound and different from the T6 coordination found in the FBP structure (Figure 
5.5a−c)(119). In addition to the Zn(II)−HCA interactions, HCA forms a hydrogen bond (H-
bond) with Glu161 of MtFBA as well as a network of H-bonds through water to Asp95 
that further drives HCA stabilization within the altered active site (Figure 5.5a). 
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Figure 5.5. Comparison of the active sites of class II FBAs. (a) Wall-eyed stereoview close-up of HCA 
interacting with MtFBA and zinc. Green mesh represents Fo − Fc density scaled to 3σ; black labels indicate 
MtFBA residues, and hot pink labels and dashed lines indicate distances measured in angstroms. (b) Wall-
eyed stereoview of MtFBA (orange) bound to HCA (pink) interacting with Zn (black) overlaid with 
MtFBA interacting with PGH (gray; PDB entry 4DEL) and Zn (purple), with dashed lines indicating 
bonding interactions. (c) Wall-eyed stereoview of MtFBA bound to HCA interacting with Zn colored as in 
panel b overlaid with MtFBA (green) interacting with FBP (cyan; PDB entry 3ELF) and Zn (magenta) with 
dashed lines indicating bonding interactions. 
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Figure 5.6. Omit maps and B-factors of atoms near HCA. (a) Wall-eyed stereo view close-up of MtFBA 
(orange) bound to HCA (pink) interacting with Zn (black). Green mesh represents a simulated annealing 
omit Fo-Fc map scaled to 3 σ. (b) Same as in (a) except blue mesh represents final 2Fo-Fc map of HCA and 
adjacent residues scaled to 1.25 σ and green mesh represents final Fo-Fc map scaled to 3 σ. (c) B-factors of 
HCA and nearby atoms ranging from 25 (dark blue) to 75 (red). 
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Examining HCA’s Specificity for Class I and II FBAs 
 
As class II FBAs share considerable sequence similarity (Figure 5.3a), HCA’s 
potential as a class II FBA broad-spectrum inhibitor was examined. A single 
concentration of HCA of 25 µM was tested for the inhibition of class II FBAs isolated 
from E. coli and methicillin-resistant S. aureus (MRSA). HCA demonstrated 42.2 ± 2.8% 
inhibition against E. coli and 64.3 ± 0.6% inhibition against MRSA (Figure 5.7). 
Conversely, class I FBAs are markedly different in sequence from class II FBAs and do 
not utilize a zinc (II) ion to perform their mechanistic function. Therefore, to investigate 
HCA’s specificity for class II FBAs over class I FBAs, the class I FBAs isolated from 
both rabbit and human muscle were tested against HCA. Unlike class II FBAs, HCA 
showed no inhibitory effects against either class I FBA even at concentrations as high as 
1 mM (Figure 5.7). 
  
Figure 5.7. Effectiveness of HCA against class I FBAs and other class II FBAs. HCA at 25 µM was 
tested for its ability to inhibit class II FBAs from E. coli and MRSA as well as class I FBAs isolated from 
either rabbit or human muscle. Error bars represent the standard deviations from the average. 
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Discussion 
HCA as a Noncompetitive MtFBA Inhibitor 
The alignment of the MtFBA−HCA structure with those of MtFBA bound with 
FBP, or PGH, illustrates that HCA does not intrude into the substrate pocket itself (Figure 
5.5b,c). Instead, incorporation of HCA into MtFBA appears to displace the Z-loop and in 
doing so blocks access of MtFBA substrates to an empty pocket (Figure 5.5b,c). The 
proximity of a noncompetitive inhibitor to a substrate pocket has been previously 
observed with a noncompetitive inhibitor, PD184352, of MAP kinase kinase 1 
(MEK1)(155). The noncompetitive nature of inhibition outlined by the mode of inhibition 
experiments combined with the structural data suggests that the MtFBA−HCA structure 
may be reflective of an EI complex found in the third model for noncompetitive 
inhibition (Figure 5.8a)(156). In this model, the inhibitor binds next to the substrate-
binding site with or without the substrate bound. When the substrate is absent, the 
inhibitor sterically hinders access of substrates to an empty site comparable to that 
observed in the structure of the MtFBA−HCA complex (Figure 5.8a). Also, the myriad of 
coordination bonds and H-bonds that HCA forms with MtFBA pulls the Zn (II) away 
from the substrate binding pocket. This would likely eliminate its availability for 
catalysis in an ESI complex in line with the third model of noncompetitive inhibition. 
Use of HCA as a Scaffold for Future MtFBA Inhibitor Development 
The persistence of tuberculosis along with the rise of many forms of drug resistant 
bacteria has supported the interest in identifying inhibitors for class II FBAs that may  
 
  105 
  
Figure 5.8. Proposed model of inhibition of HCA for MtFBA and applicability to other class II FBAs. 
(a) Cartoon adaptation of HCA’s inhibition of MtFBA according to the third model for noncompetitive 
inhibition. (b) Wall-eyed stereoview of the overlay of FBAs from M. tuberculosis (gray; PDB entry 4DEL), 
B. anthracis (blue; PDB entry 3Q94), and E. coli (teal; PDB entry 1B57). Black labels indicate MtFBA 
residues. 
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serve as viable preclinical candidates for further development as antibiotic and 
antiparasitic treatments(110-113, 116-118, 141). Although previous class II FBA inhibitor 
development efforts have been able to deliver potent substrate-based analogs selective for 
class II over class I FBAs, the recurring theme throughout studies utilizing class II FBA 
substrates as a scaffold is the necessity of these inhibitors to possess highly charged 
phosphate groups(112, 117, 141). As phosphorylation of glycolytic intermediates is a method 
for cells to retain these intermediates within the cytosol, their inclusion into class II FBA 
inhibitors has been problematic(157). In addition, the active site of class II FBA, which has 
evolved to interact with class II FBA’s highly polar substrates, is itself highly polar, 
lacking appreciable potential for hydrophobic interactions. As this form of interaction 
typically dominates protein−drug interactions, targeting the class II FBA active site has 
proved to be daunting. 
HCA sidesteps both of these issues through its distinct low-micromolar 
noncompetitive mode of inhibiting MtFBA. Specifically, HCA appears to take advantage 
of the previously overlooked fragility of the coordination of His212 of MtFBA of with Zn 
(II) along with the structural dependence of the Z-loop on that interaction to facilitate 
hydrophobic and hydrophilic contacts. At first glance, the substrate- and Zn (II)-bound 
MtFBA structures of Pegan et al., as well as the Zn(II)-bound holo-MFBA structure of 
Pegan et al., might have suggested that a stable interaction between His212 and an active 
site Zn (II) potentially existed(118, 119). In addition, a zinc-less MtFBA apo structure of de 
la Paz Santangelo et al. illustrates that the ordered structure of the Z-loop depends on the 
presence of Zn (II) within the active site(111). However, the MtFBA−HCA structure 
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suggests that even when Zn (II) is bound to the MtFBA active site, the interaction 
between His212 and the bound Zn (II) is still in flux. This flux allows HCA to supplant 
His212 with a trident coordination of the metal or a HCA−Zn(II) complex to replace the 
active site Zn (II). Naturally, additional experiments will likely be necessary to tease out 
which event is more likely. However, the MtFBA−HCA structure along with the 
biochemical and biophysical experiments illustrates that HCA prefers to be bound to 
MtFBA’s active site Zn (II) and that this Zn (II) prefers HCA over His212. 
From the MtFBA−HCA structure, this preference appears to be driven by not only 
a H-bond network formed by bonds from HCA to Asp95 and Glu161 of MtFBA that 
pulls Zn (II) away from the active site, but also hydrophobic interactions caused by the 
creation of a hydrophobic pocket that accommodates HCA’s bicyclic ring structure 
(Figure 5.5b). As hydrophobic interactions are usually sought for protein−drug 
interactions and are a largely insignificant factor in the affinity of previous inhibitors for 
class II FBAs, the presence of this feature in MtFBA−HCA interactions is particularly 
noteworthy. In addition to HCA’s distinct mode of inhibition, HCA possesses several 
features that make the compound attractive from a medicinal chemistry perspective. First, 
the compound has a low molecular mass of 189 Da and contains minimal structural 
features. Furthermore, functionality can be added at a variety of places on HCA while 
still likely maintaining druglike properties(152, 158, 159). Also, HCA appears via the 
MtFBA−HCA structure to capitalize on the unique mechanistic difference between class 
I and class II FBAs by interacting with MtFBA active site zinc and residues immediately 
surrounding it. These residues along with Zn2+ do not exist in class I FBAs. This 
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combined with the lack of measurable inhibition of mammalian class I FBAs suggests the 
HCA scaffold could represent a significant leap forward in class II FBA preclinical 
inhibitor development. 
Broad-Spectrum Potential of HCA 
Interestingly, class II FBAs can be broken down into two families (a and b) whose 
distribution among bacteria is independent of Gram staining-determined phylogenetic 
groups. Naturally, all class II FBAs have an evolutionary need to maintain an effective 
active site that binds Zn (II) and a common set of substrates. As a result, the structural 
differences between these two subfamilies are predominantly distal from their respective 
active sites and are involved in determining the diverse oligomeric states adopted by class 
II FBAs(119). This phenomenon is well represented upon comparison of residues that 
comprise the HCA-induced pocket (Figure 5.8b). Structural alignments of class IIa FBAs 
from M. tuberculosis and E. coli along with that of B. anthracis’s class IIb FBA reinforce 
the potentially conserved nature of the HCA-induced pocket (Figure 5.8b). The ability of 
HCA to significantly inhibit both the class IIa FBA from E. coli and a class IIb FBA from 
MRSA further supports the potential use of the HCA scaffold for these bacteria. Of 
course, additional experiments with these or other class II FBAs will have to be 
conducted to fully confirm HCA is acting in a manner similar to that observed in MtFBA. 
However, the initial evidence bodes well for the broad-spectrum potential of the HCA 
scaffold in further class II FBA preclinical inhibitor design efforts. 
Chapter 5 is in part a reprint of the material as it appears in Capodagli G. C., 
Sedhom W. G., Jackson M., Ahrendt, K. A., and Pegan S. D. (2014) A Noncompetitive 
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Inhibitor for Mycobacterium tuberculosis’s Class IIa Fructose 1,6-Bisphosphate 
Aldolase. Biochemistry, 53: 202-13. The dissertation author was primary researcher and 
author of this publication. 
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